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Background: Endometrial cancer is the most common gynecological cancer in high-
developed regions of the world, and the incidence has been increasing over the last half 
century, largely driven by a concurrent increase in population obesity. Primary 
treatment is surgical in most cases, but only limited preoperative risk stratification has 
been applied in traditional clinical practice. To enable more individualized treatment, 
improved methods for preoperative tumor characterization are highly warranted. 
 
Aim: To identify and evaluate new imaging markers that may aid in the preoperative 
risk stratification and tailoring of treatment in endometrial cancer. 
 
Material and methods: The studies included in this thesis are based on collected 
imaging-, clinical- and histological data from endometrial cancer patients treated at 
Haukeland University Hospital during April 2009 to November 2013. Standardized 
MR imaging data were acquired for 216 prospectively included patients with 
histologically confirmed endometrial cancer. From this cohort, four different 
subcohorts were included in study I-IV. In Paper I, three radiologists independently 
measured tumor size on conventional MR images for 212 patients. In Paper II, 
metabolic features were extracted from MR spectroscopy performed on 77 patients. In 
Paper III, texture features were extracted from MR images, using a filtration-
histogram technique in 180 patients. In Paper IV, CT imaging data were 
retrospectively collected and texture features extracted for 155 patients. In all studies, 
the respective imaging markers were evaluated as predictors of histopathological high-
risk features and survival. 
 
Results: The interobserver variability for MRI-measured tumor size is very low (ICC 
0.78-0.85) (Paper I). AP diameter greater than 2 cm independently predicts deep 
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myometrial invasion (OR 6.7, p<0.001) and CC diameter greater than 4 cm 
independently predicts lymph node metastases (OR 4.9, p=0.009) when adjusting for 
conventional MRI reading results and risk status based on preoperative endometrial 
biopsy (Paper I). CC tumor diameter has an independent impact on recurrence- and 
progression-free survival (adjusted HR 1.04, p=0.009) (Paper I). 
Tumor tissue has significantly higher MR spectroscopy-derived ratios for 
tCho/Creatine, tCho/Water and tCho/Noise than normal myometrial tissue (p<0.001 
for all) (Paper II). High tumor tCho/Water ratio is also significantly associated with 
high histological tumor grade in endometrioid tumors (p=0.02) (Paper II). No 
significant associations are found between tumor tCho-levels and recurrence- and 
progression-free survival (Paper II). 
When performing texture analysis of MR images, high tumor entropy in ADC-maps 
independently predicts deep myometrial invasion (OR 3.2, p<0.001), and high MPP in 
T1c images independently predicts high-risk histological subtype (OR 1.01, p=0.004) 
when adjusting for MRI-measured tumor volume, conventional MRI reading results 
and biopsy risk status (Paper III). Furthermore, high kurtosis in T1c images 
independently predicts reduced recurrence- and progression-free survival (adjusted HR 
1.5, p<0.001) (Paper III). 
When performing texture analysis of CT images, high tumor entropy independently 
predicts deep myometrial invasion (OR 3.7, p=0.008) and cervical stroma invasion (OR 
3.9, p=0.02) when adjusting for MRI-measured tumor volume, conventional MRI 
reading results, age and biopsy risk status (Paper IV). High value of MPP 
(MPP5>24.2) independently predicts high-risk histological subtype (OR 3.7, p=0.01) 
(Paper IV). High tumor kurtosis tends to independently predict reduced recurrence- 
and progression-free survival (adjusted HR 1.1, p=0.06) (Paper IV). 
 
Conclusions: Tumor size can be measured on preoperative conventional MRI with 
very low interobserver variability. Large tumor size predicts deep myometrial invasion, 
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lymph node metastases and poor outcome in endometrial cancer, and thus, imaging 
markers based on tumor size may improve preoperative risk stratification (Paper I). 
High choline levels, measured by MR spectroscopy, differentiate tumor tissue from 
normal tissue in endometrial cancer patients, but do not have significant prognostic 
value in our study (Paper II). 
MRI-derived tumor texture parameters predict deep myometrial invasion, high-risk 
histological subtype, and reduced recurrence- and progression-free survival in 
endometrial cancer (Paper III). CT-derived tumor texture features predict deep 
myometrial invasion and cervical stroma invasion in endometrial cancer, and also tend 
to predict high-risk histological subtype and survival (Paper IV). The image texture 
features entropy, kurtosis and MPP seem to reflect tumor heterogeneity and may aid in 
preoperative risk assessment (Paper III and IV). 
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1H Proton (1H is the most common isotope of hydrogen with one 
proton and no neutrons.) 
2D   2-dimensional 
3D   3-dimensional 
ADC   Apparent diffusion coefficient 
AP   Anteroposterior 
AUC   Area under the curve 
Ax   Axial 
Ax obl  Axial oblique 
b1000  b-value of 1000 (measure for degree of diffusion weighting in 
DWI) 
BMI   Body mass index 
CA-125  Cancer antigen 125 
CC   Craniocaudal 
ce   Contrast-enhanced 
CI   Confidence interval 
Cor   Coronal 
CSI   Chemical shift imaging 
CT   Computed tomography 
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CTTA   CT texture analysis 
DCE   Dynamic contrast-enhanced 
DNA   Deoxyribonucleic acid 
DWI   Diffusion weighted imaging 
EC   Endometrial cancer 
ER   Estrogen receptor 
ESGO   European Society of Gynaecological Oncology 
ESMO  European Society of Medical Oncology 
ESUR   European Society of Urogenital Radiology 
F   Fluorine 
FDG   Fluorodeoxyglucose 
FIGO   International Federation of Gynecology and Obstetrics 
FS   Fat saturated 
GDF-15  Growth differentiation factor 15 
HNPCC  Hereditary nonpolyposis colorectal cancer 
HR   Hazard ratio 
ICC   Intraclass correlation coefficient 
IrRC   Immune-related Response Criteria 
KRAS  Kirsten rat viral sarcoma homolog 
L1CAM  L1 cell adhesion molecule 
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LVSI   Lymphovascular space invasion 
MDC   Minimal detectable change 
min   Minutes 
ml   Milliliter 
mm   Millimeter 
msec   Millisecond 
MoMaTEC  Molecular Markers in Treatment of Endometrial Cancer 
MPP   Mean of positive pixels 
MR   Magnetic resonance 
MRI   Magnetic resonance imaging 
MRS   Magnetic resonance spectroscopy 
MRTA  MR texture analysis 
n   Number 
OR   Odds ratio 
p   Probability 
PERCIST Positron Emission tomography Response evaluation Criteria In 
Solid Tumors 
PET   Positron-emission tomography 
PR   Progesterone receptor 
PRESS  Point-resolved spectroscopy 
RECIST  Response Evaluation Criteria In Solid Tumors 
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REK   Regional etisk komité (Regional ethics commitee) 
ROC   Receiver operating characteristic 
ROI   Region of interest 
s   Seconds 
Sag   Sagittal 
SD   Standard deviation 
SLN   Sentinel lymph node 
SNR   Signal-to-noise ratio 
SSF   Spatial scale filter 
T   Tesla 
T1 Refers to T1-weighting of MR images, i.e. scan parameters set to 
enable visualization of differences in longitudinal magnetization 
recovery 
T1c T1-weighted images with intravenous contrast (in this thesis 
equivalent to VIBE +C) 
T2 Refers to T2-weighting of MR images, i.e. scan parameters set to 
enable visualization of differences in transverse magnetization 
decay 
TA Acquisition time 
tCho Total choline-containing metabolites 
TE Echo time 
TP53 Tumor protein 53 
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TR Repetition time 
TrueFISP True fast imaging with steady state precession 
TSE Turbo spin-echo 
TV   Transverse 
TVUS   Transvaginal ultrasound 
USPIO  Ultrasmall particles of iron oxide 
VIBE   Volumetric interpolated breath-hold examination 
VIBE +C  VIBE with intravenous contrast 
WHO   World Health Organization 





Cancer arising from the epithelial lining of the uterine cavity, i.e. the 
endometrium, is the most common gynecological malignancy in developed countries 
(1, 2). Overall, in these countries, endometrial cancer is the fourth most common cancer 
in women, after breast, colorectal and lung cancer. In Norway, approximately 700 new 
cases are diagnosed each year (3). The age-standardized incidence rate in Norway has 
been steadily increasing during the last half century, at least until the last decade 
(Figure 1). A similar increase of incidence has also been observed in the rest of Western 
Europe and in North America, and the obesity epidemic is believed to be the main 
driver of this increase (2, 4). 
 
Figure 1: Increasing age-standardized incidence rate (Norwegian standard 
population) of uterine cancer* over the last half century. Figure adapted from 
Cancer in Norway 2017(3). 
* Includes endometrial cancer and uterine sarcomas, the latter comprising only about 
3% of uterine corpus cancers and having a relatively stable incidence rate (5, 6).  
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Endometrial cancer is predominantly a disease of elderly women. 
Approximately 85% of cases are diagnosed in postmenopausal women (2). In Norway 
during 2013-2017, the age-specific incidence rate was highest in the age group 75-79 
years, and the median age at the time of diagnosis was 68 years (3). 
Typically presenting with abnormal vaginal bleeding, endometrial cancer is often 
diagnosed at an early stage and generally has a good prognosis. The five-year relative 
survival was 84% in Norway in the period 2013-2017 (3). However, with advancing 
disease stage at the time of diagnosis, the prognosis is substantially worsened. While 
patients with localized disease have an excellent prognosis (95% five-year relative 
survival), patients with regional- and distant spread have reported five-year relative 
survival of only 59% and 40%, respectively (3). 
 
2.2 ETIOLOGY, PATHOGENESIS AND RISK FACTORS 
No definite or isolated cause of endometrial cancer has been identified. However, 
alterations in estrogen metabolism seem to play an important role in the pathogenesis, 
in particular for endometrial cancer of endometrioid subtype. The main risk factor is 
exposure to excess and unopposed endogenous or exogenous estrogens associated with 
obesity, insulin resistance, early age at menarche, nulliparity, late-onset menopause, 
older age and use of tamoxifen (2). Increased estrogen levels, without opposing 
progesterone, induces endometrial proliferation, which may lead to hyperplasia and 
eventually cancer (7). Traditionally, a dualistic classification into Bokhman type I and 
type II endometrial cancer has been used (8). Type I cancers being estrogen-dependent, 
typically low-grade endometrioid tumors in obese patients and having a good 
prognosis, contrary to type II cancers comprising non-endometrioid, high-grade tumors 
with a worse prognosis. Although relevant for understanding endometrial cancer 
pathogenesis, this classification has been less used in recent years, as more clearly 
defined histological criteria enable a more detailed and consistent risk stratification. 
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Furthermore, endometrial cancer characterization has been complemented by more 
refined classifications based on genetic alterations (9). 
The vast majority of endometrial cancers occur sporadically, but approximately 
5% are caused by inherited genetic changes (10). Most important, Lynch syndrome, 
i.e. hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal dominant 
inherited cancer susceptibility syndrome, which predisposes for several cancer types 
including endometrial cancer. In fact, women with HNPCC have a lifetime risk of up 
to 71% of developing endometrial cancer (10). Cowden’s syndrome is another 
autosomal dominant inherited condition which is associated with up to 28% lifetime 
risk of developing endometrial cancer (11). In general, women with hereditary 
endometrial cancer are diagnosed at younger age, often in their forties (12, 13). 
 
2.3 HISTOPATHOLOGY 
As in most cancers, histopathological examination is the cornerstone for 
establishing the diagnosis of endometrial cancer. The endometrioid subtype accounts 
for about 80% of cases (14). The term endometrioid refers to endometrial-type glands 
of varying differentiation. According to the WHO classification system (15), 
endometrioid carcinoma of grade 1 consists of well-formed glands with ≤5% solid 
areas; grade 2 tumor has less differentiated glands and 6-50% solid areas; whereas a 
grade 3 tumor has poorly differentiated, distorted gland structure and >50% solid 
growth. The non-endometrioid subtype comprises tumors that are all considered high-
grade tumors: i.e. serous carcinomas (3-10% of cases), clear cell carcinomas (2-3% of 
cases), carcinosarcomas (<2% of cases) and undifferentiated carcinomas (15). 
Importantly, these histological distinctions may be difficult, and studies have reported 
substantial discordance even between experienced pathologists, e.g. in distinguishing 
high-grade endometrioid tumors from non-endometrioid tumors (16, 17). Also the 
distinction between low-grade endometrioid cancer and endometrial hyperplasia (not 
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malignancy) is difficult with reportedly substantial interobserver variability among 
pathologists (18). 
 
2.4 CLINICAL FEATURES 
2.4.1 Symptoms of endometrial cancer 
Abnormal vaginal bleeding is one of the presenting symptoms in about 90% of 
all endometrial cancer patients (2). Due to this conspicuous symptom being frequent, 
endometrial cancer is often diagnosed at an early stage – as women with abnormal 
vaginal bleeding tend to seek health care without much delay. In a postmenopausal 
setting, vaginal bleeding should always lead to further investigation, as it is reportedly 
caused by endometrial cancer in 5-10% of cases, and also other gynecological cancers 
may present as vaginal bleeding (19). With increasing age and presence of other risk 
factors, the endometrial cancer risk is even higher. In premenopausal women, abnormal 
vaginal bleeding is also an important symptom. However, this diagnosis is much more 
challenging, as only 0.33% of patients with premenopausal abnormal vaginal bleeding 
are diagnosed with endometrial cancer (20). Patients with advanced disease may also, 
due to large pelvic tumor burden or metastatic disease, present with abdominal or 
pelvic pain, abdominal distention, lower-extremity edema or weight loss. 
 
2.4.2 Biopsy and curettage 
In most cases, endometrial cancer can be easily diagnosed with an office-based 
biopsy kit, e.g. the Pipelle (with reported sensitivity 91-99%) (21). If sufficient material 
is obtained, a preliminary diagnosis including histological subtype and grade can be 
determined. If endometrial biopsy is inconclusive, the slightly more invasive and 
anaesthesia-requiring procedure; dilatation and curettage can be performed. In addition 
to histological subtype and grade, the fractionated curettage gives a preliminary 
assessment of cervical tumor involvement. A third option, is a visual guided biopsy 
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using hysteroscopy. This method yields higher accuracy than blind curettage (22, 23), 
but is more resource-demanding. Although a biopsy, regardless of method, is needed 
for diagnosis and useful for initial risk stratification, substantial discordance is reported 
when comparing histological subtype and grade in preoperative biopsy with the 
hysterectomy specimen. A large study comparing low-risk histology (endometrioid 
grade 1 or 2) and high-risk histology (endometrioid grade 3 or non-endometrioid) in 
biopsies and hysterectomy specimen found a discordance rate of 16% between biopsy 
and hysterectomy specimen (24). 
 
2.4.3 Sonography 
Transvaginal ultrasonography (TVUS) is routinely used as a first-line imaging 
method to investigate abnormal vaginal bleeding. Being highly available, inexpensive 
and without patient side-effects, TVUS is an important diagnostic tool for the 
gynecologist. Particularly in postmenopausal women, sonographic assessment of the 
endometrium is useful, reportedly yielding 96% sensitivity and 61% specificity for 
detection of endometrial cancer, when using a 5 mm threshold to define abnormal 
endometrial thickening (25). In premenopausal women there is cyclical variation in 
endometrial thickness, and thus, no valid threshold exists for ruling out malignancy. 
However, TVUS may identify benign causes of bleeding e.g. polyps and myomas. 
Regarding local tumor extent in endometrial cancer, recent advances in ultrasound 
technology have enabled experienced sonographers to achieve accuracies for 
myometrial and cervical invasion assessments comparable to that reported for magnetic 
resonance imaging (MRI) (26). TVUS still has some limitations, though, as visibility 




2.4.4 Radiological diagnostics 
In routine clinical practice, most endometrial cancer patients undergo a 
preoperative computed tomography (CT) scan of the thorax, abdomen and pelvis for 
detection of lymph node metastases and distant spread. Pelvic MRI is also established 
as a routine preoperative examination at most centers, as this method, in general, is 
considered the superior modality for assessment of local pelvic tumor extent (27). 
Additional aspects of MRI are elaborated in chapter 2.5. 18F-fluorodeoxyglucose 
positron emission tomography/computed tomography (18F-FDG PET/CT) is 
increasingly used in endometrial cancer patients. 18F-FDG PET/CT seems superior for 
detection of metastatic lymph nodes and distant spread in endometrial cancer (28-30). 
However, metastatic lymph nodes or metastatic lesions of very small size are more 
likely to be PET-negative. One 18F-FDG PET/CT study reported sensitivities of 93% 
for lesions ≥10 mm, 67% for lesions 5-9 mm and as little as 17% for lesions ≤ 4 mm 
(30). 
 
2.4.5 Serum markers and tumor tissue markers 
In routine diagnostic work-up of endometrial cancer, no blood sample analyses 
are yet implemented in decision-making. However, several studies suggest serum 
cancer antigen (CA)-125 (also used for detection and treatment monitoring in ovarian 
cancer) as a potential preoperative risk stratification tool in endometrial cancer (31-
34). High levels of calprotectin and growth differentiation factor (GDF)-15 have also 
been linked to an aggressive endometrial cancer phenotype (35, 36). 
The traditionally used histological markers related to subtype and grade are long 
known prognostic biomarkers in endometrial cancer. Along with the International 
Federation of Gynecology and Obstetrics (FIGO) staging parameters, these have been 
used to decide on optimal treatment strategy and for prognostication. However, it is 
shown that 15-20% of presumed low-risk patients will develop recurrent disease, 
whereas approximately 50% of presumed high-risk patients will not (2). Hence, several 
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histological and molecular biomarkers have been studied aiming to improve risk 
stratification in endometrial cancer. Histological lymphovascular space invasion 
(LVSI) (37), DNA ploidy status (38), estrogen- and progesterone receptor (ER/PR) 
expression (39, 40), L1CAM expression (41), TP53 expression (42) and KRAS 
amplification (43) are all biomarkers reported to have independent prognostic value. 
Recently, LVSI has been included in risk stratification guidelines from the European 
Society for Medical Oncology (ESMO) (44). The other markers mentioned above are, 
at present, not implemented in routine clinical practice. However, large prospective 
studies are ongoing (e.g. MoMaTEC2/NCT00598845) in order to determine whether 
new markers should be recommended for routine clinical implementation. 
 
2.5 MAGNETIC RESONANCE IMAGING IN ENDOMETRIAL CANCER 
2.5.1 Conventional MRI 
MRI has long been considered the imaging method of choice for preoperative 
staging of endometrial cancer (45-47). With its high soft-tissue contrast, high spatial 
resolution with minimal effect on image quality caused by surrounding skeletal parts 
and calcifications, MRI is well suited for oncological imaging in the pelvic region. Two 
perpendicular T2-weighted acquisitions, angled along the long- and short axes of the 
uterine body, are routinely performed. T1-weighted images with intravenous contrast 
are also normally included in the protocol, and the recommended contrast delay is 2 
min ± 30 s, which is reported as optimal for assessment of deep myometrial invasion 
(46). Tumor tissue is usually isointense or moderately hyperintense (relative to the 
myometrium) on T2-weighted images, and on contrast-enhanced T1-weighted images 
tumor tissue is hypointense compared to the highly vascularized myometrium (Figure 
2). Additional acquisitions perpendicular to the axis of the endocervical channel may 
improve assessment of cervical tumor invasion. Although conventional MRI has 
limited sensitivity to detect lymph node metastases, the European Society of Urogenital 
Radiology (ESUR) also recommend T1- and T2-weighted images up to the levels of 
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the kidneys for retroperitoneal lymph node assessment (46). Routinely, patients fast for 
3-6 hours prior to MRI, and a peristaltic inhibitor (glucagon or butyl-scopolamine) is 
administered intramuscularly or intravenously shortly before scanning in order to 
reduce peristalsis artifacts. 
The preoperative staging includes assessment of deep myometrial invasion 
(<50% vs. ≥50%), cervical stroma invasion, extrauterine tumor growth and presence 
of lymph node metastases. Contrast-enhanced MRI has been considered superior to 
TVUS, CT and unenhanced MRI for assessment of local tumor extent (45, 48, 49). 
However, with advances in ultrasound technology some recent publications report 
comparable results for TVUS and MRI (26). To some extent, though, all conventional 
imaging methods seem to be hampered by non-perfect accuracies for the staging 
Figure 2: FIGO stage 1b endometrial carcinoma (arrows), endometrioid grade 2, 
in a 76-year-old woman. a Sagittal T2. b Axial oblique T1 before contrast. c Axial 
oblique DWI b1000. d Axial oblique T2. e Axial oblique T1 after contrast (2 min). 
f Axial oblique ADC-map. 
ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; FIGO, the 
International Federation of Gynecology and Obstetrics. 
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parameters and limitations in reliability (27), a fact that has motivated further research 
on new imaging techniques and new approaches for image interpretation. 
 
2.5.2 Diffusion-weighted MRI 
Diffusion-weighted imaging (DWI) is often included in routine MRI 
examinations in endometrial cancer patients. Especially if MRI contrast agents are 
contraindicated, DWI can be useful in preoperative staging, as it aids in the assessment 
of myometrial invasion (50). The technique depicts tissue microstructure, as the image 
contrast is derived from the random motion of water molecules, which is restricted in 
tissue with high cell density. Endometrial cancers are typically hyperintense in high b 
value (i.e. highly diffusion-weighted) images, and have corresponding low values on 
the apparent diffusion coefficient (ADC) maps (Figure 2CF). As ADC values can be 
quantitatively measured in regions of interest (ROIs), several studies have proposed 
cutoffs for differentiation of malignant/benign/normal tissue and also for risk 
stratification in endometrial cancers (51-55). 
 
2.5.3 Dynamic contrast-enhanced (DCE)-MRI 
DCE-MRI is a functional imaging technique, in which tissue perfusion and 
vascular permeability can be visualized and quantitatively measured. Thus, an 
angiogenic tumor profile may be obtained in vivo (56). DCE-MRI-derived tumor 
parameters are reportedly associated with specific clinical and histological phenotypes 
in endometrial cancer and may also predict poor outcome (57, 58). However, the 
complexity of these image analyses and the post-processing required, warrant further 
exploration and standardization prior to possible future clinical implementation. 
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2.5.4 MR spectroscopy (MRS) 
MRS is another functional MRI technique, enabling non-invasive in vivo 
quantification of specific tissue metabolites. Most commonly, proton (1H)-MRS is 
performed, exploiting the physical phenomenon that protons in different molecules 
resonate at slightly different frequencies in high magnetic fields. Although being 
established as a valuable adjunct to conventional MRI in several cancer types (e.g. 
brain, prostate and breast cancer) (59), MRS in endometrial cancer is largely 
unexplored. However, a few small studies have reported MRS-measured choline (60-
62), lipids (63) and lactate (64) in endometrial cancers to be associated with specific 
phenotypes.  
 
2.5.5 MRI with new contrast agents 
A study using a lymph node-specific contrast agent composed of ultra-small 
particles of iron oxide (USPIO) reported substantially higher sensitivity (with no loss 
of specificity) for lymph node metastases than conventional MRI in endometrial cancer 
(65). Also in other cancer types (e.g. cervical and prostate cancer) encouraging results 
were reported a decade ago. Unfortunately, withdrawal of clinical approval of the 
contrast agent (ferumoxtran-10) has limited its use, also for research purposes. 
However, a recent reintroduction in the Netherlands with a large study on prostate 
cancer patients (66), hopefully will open the avenue for further research on the use of 
USPIO in gynecological cancers.  
 
2.6 RADIOMICS 
With advances in computer technology and information technology during the 
last decade, substantial efforts have been put into computer-assisted extraction of 
quantitative features from radiological imaging data; often referred to as radiomics. 
This approach is not limited to MRI, rather it seeks integration of multimodal imaging 
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data, and may yield complex models determining cancer aggressiveness (67). Going 
beyond the human eye and brain at image interpretation, exploration of tumor texture 
and tumor heterogeneity may reveal new insights relevant for tumor characterization 
and therapy. Such studies on endometrial cancer patients are scarce; however, a few 
publications have used radiomic approaches in MR- and PET-images, and report novel 
imaging biomarkers for prediction of high-risk disease (68, 69). 
Texture analysis, a method for quantification of heterogeneity in images, is an 
important element of radiomics, and this method is increasingly employed in clinical 
research. In oncological imaging, a typical approach would be to perform tumor 
delineation (i.e. selecting a ROI) in the acquired images – either a 2-dimensional (2D) 
ROI in a single, representative image slice or a 3-dimensional (3D) ROI comprising a 
whole tumor lesion in a multi-slice image stack. The voxels in the ROI would then be 
analyzed by a computer algorithm aiming at extracting features (e.g. entropy, kurtosis, 
skewness etc.) which could reflect biologically relevant information. Numerous 
publications have reported CT-derived texture features to be associated with tumor 
aggressiveness, treatment response and/or patient outcome in various cancer types, e.g. 
in colorectal (70), pancreatic (71), lung (72) and metastatic melanoma (73). However, 
at present, no study on CT texture analysis in endometrial cancer has been published. 
 
2.7 STAGING 
In 2009 an update of the endometrial cancer FIGO staging system was published 
(74), and at present, this is still the current staging system (Table 1). Endometrial cancer 
is surgically staged, although the term surgicopathological staging often is used (27), 
pinpointing that the final disease stage is usually not determined until the 
histopathological assessment after primary surgery (usually encompassing 




Table 1. FIGO 2009 staging system for endometrial cancer. 
 Stage  Criteria  
     
 IA  Tumor confined to the corpus uteri, <50% myometrial invasion  
 IB  Tumor confined to the corpus uteri, ≥50% myometrial invasion  
 II  Tumor invades cervical stroma, but does not extend beyond the uterus  
 IIIA  Tumor invades the uterine serosa and/or adnexae  
 IIIB  Vaginal and/or parametrial tumor involvement  
 IIIC1  Pelvic lymph node metastases  
 IIIC2  Para-aortic lymph node metastases  
 IVA  Tumor invades bladder and/or bowel mucosa  
 IVB  Distant metastases, including intra-abdominal metastases and/or 
inguinal lymph node metastases 
 
 
Table adapted from Pecorelli 2009 (74). 




Surgery is the cornerstone of primary treatment in endometrial cancer. 
Hysterectomy and bilateral salpingo-oophorectomy is the standard treatment for 
presumed stage I disease and is curative in most cases (2). The rationale for removal of 
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the adnexae is multifaceted: as part of staging to rule out ovarian metastases, to 
decrease estrogen production and thus possibly decrease estrogen as cancer driver and 
to prevent ovarian cancer (44). In young patients with low-risk disease, however, 
ovarian preservation may be discussed. Even fertility preserving management is 
sometimes an option in selected patients (75). Minimally invasive techniques 
(laparoscopy or robot-assisted surgery) are increasingly employed and are associated 
with shorter hospital stays and fewer postoperative complications (76). If stage II 
disease is suspected, radical hysterectomy (including paracervical and parametrial 
structures) has traditionally been recommended. However, a recent study found no 
survival benefit of radical hysterectomy compared with simple hysterectomy, and 
additionally, there was a higher rate of perioperative and late adverse events associated 
with radical hysterectomy (77). Thus, current European guidelines do not recommend 
radical hysterectomy as routine treatment in suspected stage II endometrial cancer, 
however it should be considered in cases of obvious involvement of the parametrium 
(44). If preoperative biopsy indicates serous carcinoma or clear cell carcinoma with a 
serous component, omentectomy is additionally recommended – even in apparent stage 
I disease (44). 
Lymphadenectomy is an integral part of the comprehensive surgical staging of 
endometrial cancer and provides a basis for prognostication and triage of patients for 
adjuvant therapy. However, prospective clinical trials have not shown a survival 
advantage associated with systematic lymphadenectomy in early-stage disease (78, 79), 
and the extent of lymphadenectomy performed varies between institutions (2). In 
apparent stage II disease, lymphadenectomy is in general recommended, and in more 
advanced disease (stage III-IV), complete macroscopic tumor debulking and 
comprehensive staging is recommended (44). In apparent stage I disease, however, 
there is some controversy on how and when to employ lymphadenectomy. Norwegian 
guidelines (revised in 2015) (80) subdivide stage I disease into three categories based 
on risk of recurrence (Table 2), which are identical to the ESMO classification 
published in 2013 (81). In the low-risk group, no lymph node sampling is 
recommended unless enlarged lymph nodes (short axis >10 mm) are identified, 
whereas in the intermediate-risk and high-risk groups, lymph node sampling is advised. 
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Furthermore, in the high-risk group both pelvic and para-aortic lymphadenectomy is 
recommended (80). Translated into clinical practice, these recommendations implicate 
a major role of the preoperative biopsy (histological type and grade) and on 
preoperative imaging (depth of myometrial invasion), possibly supported by 
intraoperative findings, when deciding whether or not lymphadenectomy should be 
performed. Awareness of the increased risk of complications associated with 
lymphadenectomy (82), and the known limitations of preoperative conventional 
imaging and even biopsy assessments, makes lymphadenectomy still an issue of 
controversy. Extensive research is undertaken to explore new biomarkers aiming at 
improving patient triage to lymphadenectomy, to which the studies comprising this 
thesis also is a contribution. 
 
Table 2. Risk of recurrence in stage I endometrial cancer. 
     
 FIGO IA  FIGO IB  
     
Endometrioid grade 1-2 Low risk  Intermediate risk  
Endometrioid grade 3 Intermediate risk  High risk  
Non-endometrioid High risk  High risk  
Table adapted from the Norwegian Gynecological Oncology Group guidelines 2015 (80). 
FIGO, the International Federation of Gynecology and Obstetrics. 
 
Sentinel lymph node (SLN) mapping has received increasing interest in 
endometrial cancer in recent years (83). The concept is intriguing, as it – at least 
theoretically – minimizes the treatment related morbidity, while maintaining the benefit 
of surgical staging. However, some elements of the technique (e.g. site of injection) are 
not fully standardized, and the importance of detecting lymph nodes with small 
metastases and isolated tumor cells (i.e. if SLN dissection is combined with 
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pathological ultrastaging) is unclear (44). Nevertheless, evidence is accumulating that 
SLN dissection may be useful in the management of endometrial cancer (84, 85). 
 
2.8.2 Adjuvant therapy 
According to the Norwegian guidelines referred to in Table 2, apparent stage I 
disease with low- and intermediate risk of recurrence should be treated with surgery 
alone. For apparent high-risk stage I disease and stage II and above, adjuvant therapy 
is recommended (80). As decisions on adjuvant therapy can be made after primary 
surgical treatment with the final histopathology report available, the preoperative 
pelvic imaging findings guides adjuvant therapy only if confirmed at 
surgicopathological staging. However, if distant metastases are suspected at 
preoperative imaging, such findings will triage patients into further investigations; 
either abdominal/regional biopsies during surgery or image guided biopsy for 
verification of suspected distant metastasis. If disseminated disease is confirmed, 
adjuvant therapy is recommended. Available adjuvant therapies are chemotherapy, 
radiation (external radiotherapy or vaginal brachytherapy) and hormonal therapy. In 
Norway, chemotherapy is the most used adjuvant treatment; recommended for high 
risk stage I and all stage II-IV. Radiation therapy is rarely given to stage I (as no 
survival benefit is documented), but is recommended for stage II when only simple 
hysterectomy has been performed. For stage III-IV radiation therapy is mainly given 
for palliative treatment. In other parts of Europe, radiation therapy is more widely used 
as part of adjunctive therapy. 
At present, no specific imaging markers are implemented in algorithms guiding 
the choice of adjuvant therapy in endometrial cancer. However, advances in molecular 
tumor profiling, functional imaging techniques and radiomics, may in the future enable 
more tailored treatment – possibly also targeted therapies. 
Regarding treatment monitoring, imaging has been a cornerstone for decades, with 
well established criteria based on conventional imaging, e.g. Response Evaluation 
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Criteria In Solid Tumors (RECIST), based solely on size of tumor lesions, published 
in 2000 and revised in 2009 (86). In recent years, as novel therapies and new imaging 
techniques have been introduced, more adapted response evaluation criteria have also 
been proposed, e.g. the Choi criteria in gastrointestinal stromal tumors treated with 
tyrosine kinase inhibitors, the Immune-related Response Criteria (IrRC) adapted for 
immune therapy and the Positron Emission tomography Response evaluation Criteria 
In Solid Tumors (PERCIST) incorporating metabolic changes in tumor lesions 
assessed by PET imaging (87). 
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3 Specific background and aims of the study 
3.1 SPECIFIC BACKGROUND 
Endometrial cancer is the most common gynecological cancer in high-developed 
regions of the world, and the incidence has been increasing over the last half century, 
largely driven by a concurrent increase in population obesity (1, 2). Staging of 
endometrial cancer is surgical, and the treatment strategy and prognosis are 
traditionally based on the FIGO stage and histological subtype and grade determined 
from the hysterectomy specimen (35, 74). To enable more individualized surgical 
treatment, improved methods for preoperative risk stratification are highly warranted. 
Imaging is mandatory in the diagnostic work-up of endometrial cancer, and provides 
information important for the preoperative decision-making, e.g. whether or not to 
perform lymphadenectomy. MRI is the preferred modality for assessment of local 
tumor extent (27, 47). However, conventional MRI has shortcomings in predicting 
FIGO stage (88), and interobserver variability between radiologists also represents a 
source of inaccuracy (89). Thus, we aim at identifying novel, robust and accurate 
imaging markers that may aid in the preoperative risk stratification and tailoring of 
treatment in endometrial cancer. 
 
3.2 AIMS OF THE STUDY 
1. To explore associations between preoperative tumor size measured on MR 
images and the surgical pathological staging parameters: deep myometrial 
invasion, cervical stroma invasion and lymph node metastases. Secondly, to 
assess the interobserver variability for the different tumor size measurements 
and to explore their prognostic value (Paper I). 
 
2. To explore whether preoperative MR spectroscopy-derived tumor choline levels 
are associated with clinical/histological features or survival in endometrial 
cancer (Paper II). 
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3. To explore whether tumor texture features from preoperative MRI are related to 
known prognostic factors (deep myometrial invasion, cervical stroma invasion, 
lymph node metastases, and high-risk histological subtype) and to outcome in 
endometrial cancer patients (Paper III). 
 
4. To explore whether tumor texture features from preoperative CT are related to 
known prognostic histopathological factors (deep myometrial invasion, cervical 
stroma invasion, lymph node metastases and high-risk histological subtype) and 
to outcome in endometrial cancer patients (Paper IV). 
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4 Materials and methods 
4.1 PATIENTS AND DATA COLLECTION 
The studies included in this thesis are based on collected data from endometrial 
cancer patients treated at Haukeland University Hospital during April 2009 to 
November 2013. In this time period, patients referred with suspected endometrial 
cancer had clinical examination, transvaginal ultrasound and biopsy and underwent 
preoperative pelvic 1.5T MRI using a standardized imaging protocol (Table 3). Images 
were prospectively transferred to a research database and subsequently de-identified. 
The research imaging archive was administered by the Department of Radiology at 
Haukeland University Hospital. Clinical, histological and follow-up data were 
collected by review of patient hospital records and from correspondence with 
responsible physicians if follow-up was continued outside hospital. These data were 
recorded in a separate database administered by the Department of Obstetrics and 
Gynecology at Haukeland University Hospital. Patients with a final diagnosis different 
from endometrial cancer after surgical pathological staging were excluded from both 
databases. Follow-up data have been registered until January 2017. Patient status has 
been recorded as either “alive and well”, “alive with active disease”, “dead from other 
cause”, “dead with disease, but not due to active disease” or “dead from disease”. Data 
on recurrence and/or progression have been recorded as either “no recurrence”, 
“recurrence from presumed cured disease”, “stable metastatic disease” or “progressive 
metastatic disease”. These recordings have enabled recurrence- and progression-free 
survival to be used as endpoint in the current studies. All patients signed an informed 
consent form prior to the collection of data, and the studies were conducted under 
institutional review board approved protocols (REK Vest #2009/2315; 2015/2333). 
 In Paper I, a total of 252 patients who had undergone MRI were assessed. In 36 
patients, the surgical pathological staging did not confirm endometrial cancer, and 
these were excluded. Additionally 4 patients were excluded due to incomplete FIGO 
staging (only curettage in 3 patients having substantial co-morbidity and tumor 
reduction surgery in 1 patient). Thus, the final study cohort in Paper I comprised 212 
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consecutive endometrial cancer patients with complete FIGO staging, imaged during 
April 2009 to November 2013 (Figure 3). 
In Paper II, 95 patients with confirmed endometrial cancer at subsequent 
staging, underwent MR spectroscopy (MRS) and were prospectively included in the 
MRS imaging database. Of these, 15 patients were excluded due to poorly defined 
tumors, considered difficult to reliably analyze, and 3 patients were excluded due to 
poor spectral quality. Thus, the final study cohort comprised 77 patients (a subgroup 
of the study cohort in Paper I (Figure 3)) who underwent MRS in addition to 
conventional MRI during June 2009 to January 2012. 
In Paper III, 216 consecutive endometrial cancer patients underwent MRI 
during April 2009 to November 2013. Of these, 33 were excluded due to small or 
poorly defined tumors, and 3 due to major image artifacts. Thus, 180 patients were 
included for MR texture analysis. This study cohort was largely overlapping with the 
study cohort in Paper I (Figure 3). 
 In Paper IV, the clinical imaging records of the 180 patients in Paper III were 
retrospectively examined. In total, 169 patients had available CT images. Of these, 14 
were excluded due to poorly defined tumors, considered ineligible for reliable texture 
analysis. Thus, 155 patients were included for CT texture analysis in Paper IV (a 
subgroup of the study cohort in Paper III (Figure 3)). The CT imaging of these 155 
patients was performed during April 2009 to November 2013, and these imaging data 
were retrospectively collected from different local hospitals in Western Norway (the 
majority from Haukeland University Hospital). Contrary to the MR imaging data in 
Paper I-III, the CT imaging data in Paper IV were not originally intended for research 
purposes, and thus, we are unable to report specific information on scanner types and 
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T2 TSE Sag 4920/95 3 256×256 180×180 4:03 min 
* T2 TSE Ax obl 6310/95 3 256×256 180×180 3:04 min 
FS T1 VIBE Ax obl 7.23/2.55 2 192×192 250×250 0:35 min 
* FS T1 VIBE +C 
(2 min delay) 
Ax obl 7.23/2.55 2 192×192 250×250 0:35 min 
       
Abdominal 
conventional: 
      
T1 Axial 128/4.76 6 256×256 380×380 0:36 min 
T2 TrueFISP Axial 3.59/1.51 4 256×256 380×380 0:48 min 
T2 TrueFISP Cor 3.57/1.51 4 192×192 300×300 0:12 min 
       
Pelvic DWI:       
DWI b0_1000 Ax obl 3100/79 5 128×128 300×300 2:38 min 
* ADC-map Ax obl  5 128×128 300×300  
       
Pelvic 1H-MRS:       




12×12×12  11:36 min 
       
*Sequences used for MRI texture analysis. 
1H, proton; ADC, apparent diffusion coefficient; Ax obl, axial oblique (i.e. perpendicular to the long axis 
of the uterus); C, intravenous contrast; Cor, coronal; CSI, chemical shift imaging; DWI, diffusion-
weighted imaging; FS, fat saturated; PRESS, point-resolved spectroscopy; Sag, sagittal; T1, T1-weighted 
imaging; T2, T2-weighted imaging; TA, acquisition time; TE, echo time; TR, repetition time; TrueFISP, 
true fast imaging with steady state precession; TSE, turbo spin-echo; VIBE, volumetric interpolated 
breath-hold examination. 
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4.2 IMAGE ANALYSES 
4.2.1 Conventional MRI reading  
The conventional MR images in Paper I, comprising T2-weighted images, 
diffusion-weighted images including ADC-maps and contrast-enhanced T1-weighted 
images, were de-identified and read independently by three observers who were 
blinded for tumor stage, histological diagnosis and patient outcome. Observer 1 and 2 
were consultants with more than 10 years of experience with pelvic MRI. Observer 3 
included two junior radiologists (both having approximately 4 years of experience with 
pelvic MRI); one read the first 105 MRI examinations and the other read the following 
107 examinations. All observers reported the imaging findings in a standardized form 
(see Appendix). The maximum tumor diameters were measured in three orthogonal 
planes: anteroposterior (AP) and transverse (TV) diameter on axial oblique 
(perpendicular to the long axis of the uterus) contrast-enhanced T1-weighted images 




Figure 4: Transverse (TV) and anteroposterior (AP) tumor diameters measured on 
axial oblique contrast-enhanced T1-weighted image (left) and craniocaudal (CC) 
tumor diameter measured on sagittal T2-weighted image (right) in a 64-year-old 
woman with FIGO stage 1b endometrial carcinoma (endometrioid grade 1). 
 42
Tumor volume was estimated using the following equation: AP diameter × TV 
diameter × CC diameter × 0.5. Presence of deep myometrial invasion (tumor invading 
half or more of the myometrium), cervical stroma invasion (disruption of the low-signal 
intensity cervical stroma on T2-weighted images), and enlarged lymph nodes (largest 
short-axis diameter ≥10 mm) were also recorded. Before reading the MR images in the 
study cohort, each observer independently read five cases, which then were discussed 
to achieve a common understanding of the image reading criteria applied. The five pilot 
cases were not included in the study cohort. 
A consensus score was established for the registered parameters using the 
majority score for categorical variables and the median value for continuous variables. 
These data have also been used for comparison in Paper II-IV. 
 
4.2.2 MR spectroscopy (1H-MRS) 
All patients in Paper II underwent localized multivoxel point-resolved 
spectroscopy (PRESS) with a 12 × 12 × 12 matrix manually placed to cover the tumor 
region in all planes. Images were de-identified and assessed on a Syngo workstation by 
one radiologist (with 5 years of experience in pelvic MRI) and one spectroscopist (with 
6 years of experience in MRS) who were blinded for tumor stage, histological diagnosis 
and patient outcome. The radiologist manually selected representative voxels from 
tumor tissue and adjacent normal tissue (myometrium), respectively (Figure 5). The 
spectroscopist assessed the spectral quality of the selected voxels. After excluding 
patients with small or poorly defined tumors, considered hard to reliably analyze 
(n=15), and patients with poor spectral quality (with tCho SNR < 2) in tumor voxels 
(n=3), a total of 77 patients were included in the study. Spectral data were analyzed 
using the java-based software jMRUI v5.2 for quantification of total choline-containing 
compounds (tCho) at 3.22 ppm, creatine at 3.03 ppm, water at 4.7 ppm and average 
noise level at 8.0-9.0 ppm. Three tCho ratios were generated: tCho/Creatine, 
tCho/Water and tCho/Noise. 
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Figure 5: T2-weighted MR images showing tumor voxel (yellow arrow) and non-
tumor (myometrium) voxel (orange arrow) from a 55-year-old woman with FIGO 
stage 1a endometrial cancer (endometrioid, grade 1). Corresponding MR spectra are 
shown to the right. Notice the high choline level (tCho peak) in tumor compared with 
non-tumor tissue. 
 
4.2.3 Texture analysis of MR- and CT images 
In Paper III and IV de-identified contrast-enhanced T1-weighted images 
(n=180), T2-weighted images (n=180), ADC-maps (n=177) and contrast-enhanced CT 
images (n=155), were exported to the commercially available research software 
TexRAD (TexRAD Ltd, part of Feedback Plc, Cambridge, UK). Regions of interest 
(ROIs) were drawn on the slice displaying the largest cross-sectional tumor area, 
separately on the respective image series, aiming at including all viable tumor tissue. 
The ROIs were processed using a filtration-histogram technique based on Laplacian of 
Gaussian spatial bandpass filtering, in which image elements of different sizes were 
enhanced corresponding to spatial scale filter (SSF) from 2-6 mm, i.e. fine (2 mm), 
medium (3-5 mm) and coarse texture (6 mm) (Figure 6). Based on texture 
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quantification in tumor ROIs, the parameters mean, standard deviation (SD), entropy, 
mean of positive pixels (MPP), skewness and kurtosis were calculated. Unlike CT 
images with standardized pixel values (measured in Hounsfield units), T1-weighted 
and T2-weighted MR images do not have standardized pixel values. Furthermore, the 
mean intensity does not reflect heterogeneity per se, and thus, the parameters mean and 
MPP in native (SSF=0) images (which equals mean, as no pixels in native MR images 
have negative values), was omitted in further analyses of all MR images. 
 
Figure 6: Endometrial carcinoma manually segmented (blue line) on contrast-
enhanced T1-weighted MR image, T2-weighted MR image, ADC-map and contrast-
enhanced CT image from the same 52-year-old postmenopausal woman diagnosed 
with FIGO stage 1b disease (endometrioid, grade 1). Successive filtered images 
(spatial scale filter [SSF] 2-6) to the right. 
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4.3 STATISTICAL METHODS 
4.3.1 Sample size 
To assess the risk of type II errors in our analyses, an estimation of 
recommended cohort size was done by Χ2 test using the software East4 2005 (Cytel 
Software Corp). To achieve 90% power of detecting a 20% higher occurrence of a 
biomarker in one risk category versus another (e.g. 25% in patients with lymph node 
metastases versus 5% in patients with no lymph node metastases) at a 5% significance 
level, 101 patients were needed. Furthermore, to reach 90% power to detect a 30% 
difference in 5-year survival (e.g. 90% for patients with normal levels of a biomarker 
versus 60% for patients with abnormal levels of a biomarker) at a 5% level of 
significance, 65 patients were needed, assuming a positive to negative ratio of the 
markers of 1:3. Thus, Paper II (n=77) had a somewhat small study cohort (no more 
eligible cases were available in the imaging database), while Paper I (n=212), III 
(n=180) and IV (n=155) had adequate study cohorts. 
 
 
4.3.2 Normality testing  
All image-derived variables were tested for normality by the Kolmogorov-
Smirnov and Shapiro-Wilk tests. The majority of the variables did not have normal 
distribution, thus non-parametric tests were used for further statistical analyses in 
Paper I-IV. 
 
4.3.3 Associations between image-derived variables and clinical and histopathology-
based variables 
Image-derived variables in Paper I-IV were analyzed in relation to clinical and 
histological tumor and patient characteristics using Mann-Whitney U test, Kruskal-
Wallis H test, Jonckheere-Terpsta trend test, Pearson Χ2 test, and binary logistic 
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regression analysis. Receiver operating characteristic (ROC) analyses were performed 
to assess the diagnostic value of the image-derived variables in Paper I, III and IV. 
ROC analyses were also applied to determine the best cutoff values for tumor size 
(Paper I) and MRI- and CT texture variables (Paper III and IV) selecting the highest 
Youden index, and thereby achieving the best separation between groups. McNemar 
test was used for pairwise analysis of differences in sensitivity, specificity and accuracy 
among image-derived variables, i.e. comparing tumor size measurements with 
conventional MRI reading (Paper I) and MRI texture variables to conventional MRI 
reading (Paper III). To assess whether image-derived variables were independent 
predictors of high-risk endometrial cancer, multivariable binary logistic regression 
analyses were performed including the following covariates: preoperative biopsy risk 
status (low risk defined as endometrioid grade 1-2 versus high risk defined as 
endometrioid grade 3 and non-endometrioid) (Paper I, III and IV), conventional MRI 
findings (Paper I, III and IV) and patient age (Paper IV only). 
 
Spearman’s bivariate correlation test was used to explore correlations between 
the different image-derived variables (Paper II, III and IV). In Paper II, comparison 
of MR spectroscopic features in tumor tissue and normal tissue was performed with 
related-samples Wilcoxon signed rank test. 
 
4.3.4 Interobserver variability 
In Paper I, intraclass correlation coefficient (two-way random model, 
calculated from single measurement and based on absolute agreement) was used to 
assess the reliability of tumor size measurements. Minimal detectable change (MDC = 
1.96 × standard error of the mean × √2) for the measured diameters was also reported. 
In Paper II-IV the interobserver variability was not assessed. 
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4.3.5 Survival analyses 
In Paper I, III and IV, differences in time to recurrence (for patients considered 
cured by primary treatment) or progression (for patients known to have residual disease 
after primary treatment) among patient groups defined by image-derived biomarkers 
were assessed by the Mantel-Cox (log-rank) test. A similar method was used in Paper 
II, but here the Mantel-Cox (log-rank) linear trend test was applied on MR 
spectroscopy-derived continuous variables stratified into quartiles. In Paper I and IV 
consecutive patient groups with similar survival were merged in the Mantel-Cox tests 
and the corresponding Kaplan-Meier plots.  
In Paper I, III and IV, the Cox proportional hazards model was used in 
univariable and multivariable analyses to study the effect on recurrence- and 
progression-free survival of image-derived continuous variables. In the multivariable 
analyses we aimed to adjust for relevant prognostic information available 
preoperatively, and included the following covariates: preoperative biopsy risk status 
(Paper I, III and IV), conventional MRI findings (Paper III and IV) and patient age 
(Paper IV only). 
 
4.3.6 Determination of significance level 
In Paper I and II, all reported P values were generated by two-sided tests and 
considered significant when <0.05. 
In Paper III, a customized modification of Bonferroni correction was applied, 
in which the number of effective tests was arbitrarily estimated as 25 (from originally 
87 texture variables being extensively correlated), leading to P values <0.002 (in two-
sided tests) being considered significant. In Paper IV, 36 CT derived texture variables 
were generated. With adjustment for inter-variable correlations, the significance level 
was set to 0.0025. With this significance level for the 36 individual tests, a random 
allocation (without replacement) of the 36-variate texture variables to outcome group 
had approximately 5% chance of at least one significant result. 
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In the multivariable analyses in Paper III and IV, a traditional significance level 
of 0.05 was used. 
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5 Main results 
In Paper I, we investigate the relationship between preoperative MRI measured 
tumor size and the surgical pathological staging parameters deep myometrial invasion, 
cervical stroma invasion and lymph node metastases – and survival – in a cohort of 212 
consecutive patients with histologically confirmed endometrial cancer. When adjusting 
for risk status based on preoperative endometrial biopsy and other tumor size variables, 
we find that AP tumor diameter independently predicts deep myometrial invasion 
(p=0.001), and that CC tumor diameter tends to independently predict lymph node 
metastases (p=0.06).  
Based on ROC curves, the following tumor size cutoff values are identified: AP 
diameter greater than 2 cm predicts deep myometrial invasion (unadjusted odds ratio 
(OR) 12.4, p<0.001; adjusted OR 6.7, p<0.001) and CC diameter greater than 4 cm 
predicts lymph node metastases (unadjusted OR 6.2, p<0.001; adjusted OR 4.9, 
p=0.009) (adjusted ORs when including conventional MRI reading results [indicating 
presence of deep myometrial invasion and lymph node metastases, respectively] and 
risk status based on preoperative endometrial biopsy). Large tumor size is also 
associated with reduced recurrence- and progression-free survival. When adjusting for 
risk status based on preoperative endometrial biopsy and other tumor size variables, 
CC tumor diameter has an independent impact on recurrence- and progression-free 
survival (adjusted hazard ratio (HR) 1.04, p=0.009). The interobserver variability for 
the different size measurements was very low (ICC 0.78-0.85). 
 
In Paper II, we quantify levels of choline-containing metabolites (tCho) from in 
vivo magnetic resonance spectroscopy (MRS) of 77 endometrial cancer patients. The 
overall aim is to explore whether tumor tCho-levels are associated with 
clinical/histological patient and tumor characteristics and patient outcome. We also 
compare tCho-levels in tumor tissue and normal tissue (myometrium). We find that 
high tumor tCho/Water ratio is significantly associated with histological tumor grade 
in endometrioid tumors (p=0.02), and that tumor tissue has significantly higher ratios 
 50
for tCho/Creatine, tCho/Water and tCho/Noise than normal myometrial tissue 
(p<0.001 for all). No significant associations are found between tumor tCho-levels and 
recurrence- and progression-free survival. 
 
In Paper III, we extract texture features from tumor ROIs in MR images, using a 
filtration-histogram technique, in 180 endometrial cancer patients, and explore whether 
these tumor texture features are related to known prognostic features (deep myometrial 
invasion, cervical stroma invasion, lymph node metastases, and high-risk histological 
subtype) and to outcome (recurrence- and progression-free survival). The multivariable 
analyses included risk status from preoperative biopsy, conventional MRI reading 
results and MRI measured tumor volume – in addition to the highest ranked MRI 
derived texture features. We find that high tumor entropy in apparent diffusion 
coefficient (ADC) maps independently predicts deep myometrial invasion (OR 3.2, 
p<0.001 for entropy at filter level 6), and high MPP in T1c images independently 
predicts high-risk histological subtype (OR 1.01, p=0.004 for MPP at filter level 4). 
Furthermore, high kurtosis in T1c images independently predicts reduced recurrence- 
and progression-free survival (HR 1.5, p<0.001 for kurtosis at filter level 2). 
 
In Paper IV, we apply the same methods as in Paper III to extract texture features 
from tumor ROIs from contrast-enhanced CT images in 155 endometrial cancer 
patients. These are also analyzed in relation to known prognostic features (deep 
myometrial invasion, cervical stroma invasion, lymph node metastases, and high-risk 
histological subtype) and to outcome (recurrence- and progression-free survival). The 
multivariable analyses included risk status from preoperative biopsy, conventional 
MRI reading results, MRI measured tumor volume and patient age – in addition to the 
highest ranked CT derived texture features. We find that high tumor entropy (at filter 
level 6) independently predicts deep myometrial invasion (OR 3.7, p=0.008) and 
cervical stroma invasion (OR 3.9, p=0.02). High MPP (at filter level 5) tends to 
independently predict high-risk histological subtype (OR 1.01, p=0.10), and when a 
cutoff based on the highest Youden index is applied, MPP5>24.2 independently 
predicts high-risk histological subtype in the same multivariable model (OR 3.7, 
 51 
p=0.01). None of the CT derived texture features independently predicts lymph node 
metastases. High tumor kurtosis tends to independently predict reduced recurrence- 




6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Patient series 
The patient cohorts studied in this thesis originate from a population-based 
hospital cohort (Haukeland University Hospital). As elaborated in chapter 4.1, MRI 
data from newly diagnosed endometrial cancer patients at Haukeland University 
Hospital have been consecutively and prospectively included in an imaging database 
for research purposes since 2009. Haukeland is the main hospital in Hordaland County 
and serves approximately 10% of the Norwegian population. Age distribution, 
incidence and stage distribution has been demonstrated to be similar in endometrial 
cancer patients in Hordaland and in Norway as a whole (3). Patients referred for 
treatment of endometrial cancer are routinely submitted to MRI investigation, thus, in 
general, only patients with contraindications to MRI (e.g. severe claustrophobia or 
dementia) do not undergo MRI. Of 360 endometrial cancer patients treated at 
Haukeland who consented to be included in the clinical research database for the period 
April 2009 - November 2013, preoperative MRI was performed for 216 patients in 
accordance with a standardized protocol at Haukeland. Many of the other patients had 
MRI examinations performed at other local hospitals, but these images were not used 
in the current studies. The study cohorts in Paper I-IV are similar to the total 
endometrial cancer population in age, histological type and FIGO stage distribution 
(Table 4). It is clear, however, that the advanced image analyses in Paper II-IV are not 
applicable to very small tumors, which explains the somewhat lower proportion of 
stage IA cancers in these cohorts (Table 4). Eligibility criteria for selecting patients to 




Table 4. Patient and tumor characteristics for the whole endometrial cancer population 
treated at Haukeland University Hospital during April 2009 to November 2013 and the 
















Median age (years) 67 66 66 66 67 68 
FIGO stage       
 I (not specified) 1% 0 0 0 0 0 
 IA 51% 54% 55% 38% 48% 47% 
 IB 21% 22% 23% 34% 25% 27% 
 II 8% 10% 10% 10% 12% 10% 
 IIIA 1% 0 0 0 0 0 
 IIIB 2% 1% 1% 1% 2% 2% 
 IIIC1 6% 6% 6% 9% 7% 7% 
 IIIC2 3% 4% 4% 7% 4% 4% 
 IV (not specified) 1% 0 0 0 0 0 
 IVA 2% <1% 0 0 <1% 1% 
 IVB 3% 1% <1% 1% 2% 2% 
 Incomplete FIGO staging <1% <1% 0 0 0 0 
Histological subtype       
 Endometrioid 76% 81% 81% 79% 79% 78% 
 Clear cell 4% 3% 3% 4% 3% 3% 
 Serous 12% 10% 10% 9% 11% 10% 
 Carcinosarcoma 5% 4% 4% 7% 5% 6% 
 Adenosquamous <1% 0 0 0 0 0 
 Undifferentiated/others 3% 2% 2% 1% 2% 3% 
Histological grade 
in endometrioid tumors (%) 
      
 Grade 1 51% 50% 51% 39% 45% 43% 
 Grade 2 28% 29% 29% 34% 32% 32% 
 Grade 3 17% 18% 17% 26% 21% 23% 
 Ungraded 4% 3% 4% 0 1% 2% 
 
FIGO stage refers to the International Federation of Gynecology and Obstetrics stage according to 2009 criteria. 
EC, endometrial cancer. 
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6.1.2 Imaging protocols 
In Paper I-III standardized protocols were used for image acquisition, which 
makes our imaging data homogenous and potentially increases reproducibility. 
Furthermore, in Paper I and III, the acquisition of the T2-weighted and contrast-
enhanced T1-weighted MR images were based on guidelines from the European 
Society of Urogenital Imaging (ESUR) published in 2009 (46), which implies that 
images are expected to be similar to those at comparable institutions. However, when 
performing MRI texture analysis (Paper III), scanner specific settings in image 
reconstruction (e.g. intensity adjustment, edge enhancement, smoothing etc.) may 
theoretically affect the results, as the ESUR guidelines did not give details at this level. 
ESUR guidelines also did not give specific recommendations on acquisition of 
diffusion-weighted images analyzed in Paper III. However, our protocol was similar 
to those reported in comparable previous studies (51, 90, 91). Furthermore, reported 
tumor ADC values for endometrial cancer tissue are quite similar in spite of differences 
in the employed diffusion imaging protocols (with b values of 0/800, 0/1000 and 
0/500/1000) (88). Paper II had a relatively small study cohort, and the MRS 
acquisitions were performed on a 1.5T scanner, which is known to yield a lower signal-
to-noise ratio compared to 3T or higher fields (92). Thus, the paucity of significant 
findings in this study should be interpreted with caution. 
In Paper IV, CT images were retrospectively collected from different local 
hospitals in Western Norway, and thus, were not acquired using a standardized 
protocol. However, all patients were imaged in a routine clinical setting as part of the 
diagnostic workup of endometrial cancer, and although the imaging data in the study 
were somewhat heterogeneous, the positive findings may suggest that this method is 
rather quite robust. 
 
6.1.3 Image analyses 
The tumor size measurements in Paper I, comprising three orthogonal tumor 
diameters and subsequent estimation of tumor volume (AP × TV × CC × 0.5), can be 
considered as a routine method in oncological image interpretation. Similar methods 
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are also previously employed in endometrial cancer MRI studies (93, 94). The MR 
spectroscopy acquisitions in Paper II were performed with a multivoxel technique, 
which increases post-processing options, i.e. selected tumor areas can be analyzed 
retrospectively. The post-processing software and method used for spectral fitting in 
our study, are well established in research (95, 96). Limiting our metabolite of interest 
to choline (total choline-containing metabolites (tCho)) only, was decided after 
literature review and for practical purposes. An inherent limitation of in vivo MR 
spectroscopy is that metabolite levels are quantified as relative concentrations rather 
than absolute. Thus, we generated the ratios tCho/Creatine, tCho/Water and 
tCho/Noise, which is in line with previous MRS studies (61, 62, 97). In Paper III and 
IV, tumor texture analysis was performed on MR- and CT images, respectively, using 
the software TexRAD, which is an established research software which has been 
featured in more than 100 PubMed listed publications. This image post-processing tool, 
employing a filtration-histogram technique for texture analysis, has previously yielded 
predictive and prognostic imaging biomarkers in several cancer types (98). It is clear, 
however, that the feature extraction provided in TexRAD (six features only: mean, 
standard deviation, skewness, entropy, mean of positive pixels and kurtosis) covers 
only a small part of the wider range of available texture features (99). 
 
6.1.4 Reproducibility and reliability 
In general, the results in this thesis are limited by imaging data derived from a 
single institution (except Paper IV), analyses being performed by a single observer 
(except Paper I) and not yet being internally or externally validated. Additionally, 
intraobserver variability has not been assessed. Thus, validation across observers, 
centers and platforms are warranted. Particularly the complex image analyses in Paper 
II-IV should be reproduced in different cohorts using a priori cutoffs prior to potential 
implementation in clinic. 
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6.2 DISCUSSION OF RESULTS 
6.2.1 Interobserver variability 
Conventional MRI reading in endometrial cancer patients includes evaluation 
of local pelvic tumor extent (depth of myometrial invasion, cervical stroma invasion, 
extrauterine tumor extension, etc.) and presence of lymph node metastases on a strict 
anatomical basis (45). For diagnosing deep myometrial invasion, the interobserver 
agreement varies from fair to good in different studies (89). For cervical stroma 
invasion and lymph node metastases, the same studies report moderate to good 
interobserver agreement. This knowledge about substantial interobserver variability as 
a source of inaccuracy has also motivated an exploration of new imaging biomarkers, 
potentially less hampered by interobserver variability, in endometrial cancer. In Paper 
I, we found the interobserver variability of tumor size measurements on MRI to be very 
low (ICC 0.78-0.85), and furthermore, there was no significant difference in diagnostic 
performance among experienced and non-experienced readers. Thus, tumor size 
measurements on MRI seem to represent an attractive alternative as robust imaging 
biomarkers complementing staging parameters derived from conventional reading. 
In Paper II-IV, we explored more complex imaging biomarkers, all of which 
were quantitative in nature. Not including intra- or interobserver analyses in these 
studies is clearly a limitation. In Paper II, the subjectivity in selecting voxels for 
spectroscopic analysis putatively represents the main source of variability. The further 
steps in the assessment, including spectral fitting and quantification of metabolites, 
were performed according to a fixed and automated algorithm, expected to reduce 
intra- and inter-observer variability. Similarly, in Paper III and IV the manual image 
slice selection and tumor delineation, although based on fixed criteria, are potential 
sources of variability. The fixed algorithm in the subsequent image texture analysis, 
however, is expected to yield highly reproducible results. On the other hand, when 
comparing different studies with complex, multi-step image analyses, even small 
variations in software settings (e.g. jMRUI in Paper II and TexRAD in Paper III-IV) 
may affect the results. An additional challenge with TexRAD is that the image filtration 
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technique is not open-source, and thus, the results are difficult to validate based on 
other software platforms. 
 
6.2.2 Tumor size measurements on MR images 
In Paper I three observers independently measured tumor size in three 
orthogonal planes on MR images with very low interobserver variability. Furthermore, 
the study demonstrated significant associations between tumor size and high-risk 
endometrial cancer, in accordance with a study by Todo et al (94) reporting high 
volume index (defined as maximum AP × TV × CC tumor diameter measured on MRI) 
to be associated with deep myometrial invasion. Unlike Todo et al, we aimed at 
exploring the respective tumor diameters as individual variables. In a multivariable 
model including preoperative risk status based on endometrial biopsy, AP tumor 
diameter was the only size variable independently predicting deep myometrial 
invasion. Based on ROC curve analysis, a cutoff of 2 cm was proposed. Using the 
surgicopathological staging as the gold standard, this relatively simple size criteria (AP 
tumor diameter >2 cm) achieved comparable accuracy (sensitivity, specificity) to 
conventional MRI reading for identification of deep myometrial invasion: 79% (66%, 
86%) versus 74% (70%, 77%), respectively. The specificity for AP tumor diameter >2 
cm (86%) was significantly higher than that of conventional reading (77%; p=0.02, 
McNemar test), whereas accuracy and sensitivity was not significantly different.  
In daily radiologic practice, scoring depth of myometrial invasion (<50% or 
≥50%) on MRI is a continuing challenge. The present study also illustrates this, 
demonstrating disagreement between three radiologists in as much as 46% (98/212) of 
the patients. In this subgroup, AP diameter >2 cm had significantly higher accuracy 
than conventional MRI consensus reading for identification of deep myometrial 
invasion: 76% versus 64% (p=0.05, McNemar test). Specificity was also significantly 
higher: 88% versus 69% (p=0.01, McNemar test), whereas sensitivity was equal at 
56%. A potential clinical application of this finding could be the following reading 
strategy: If the radiologist is in doubt when scoring depth of myometrial invasion, the 
(AP) tumor size cutoff should aid in deciding the depth of myometrial invasion. 
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In the literature, a macroscopic tumor diameter greater than 2 cm in 
hysterectomy specimens has been reported to independently predict lymph node 
metastases and survival (100), but results in other studies are equivocal (101, 102). 
Another study based on macroscopic inspection of the hysterectomy specimen, 
reported a maximum tumor diameter greater than 3.75 cm (measured by the 
pathologist) to independently predict deep myometrial invasion, distant recurrence and 
death (103). In our study, median (consensus) CC diameter was 3.1 cm, whereas 
median AP diameter was 1.6 cm and median TV diameter 2.6 cm. In the vast majority 
of patients, the CC diameter was the largest tumor diameter, so our proposed cutoff of 
CC diameter >4 cm (based on ROC curve analysis for prediction of lymph node 
metastases) seems to be in line with Chattopadhyay et al (103). Even if tumor 
measurements on macroscopic fresh tissue are not directly comparable to tumor 
measurements on MRI, large tumor size as a predictor of high-risk endometrial cancer 
seems to be broadly supported in the present literature. 
In a survival analysis using recurrence- and progression-free survival as 
endpoint, we also found CC diameter to be an independent prognostic factor. The 
combination of CC diameter >4 cm and AP diameter >2 cm was proposed as an easily 
applicable criteria for preoperative risk stratification. In current literature, comparable 
survival data is scarce, and we suggest further exploration of tumor size parameters 
along with other potential biomarkers available in a preoperative setting.  
 
6.2.3 Choline-levels measured by MR spectroscopy 
Choline is a marker of active proliferation and cell membrane turnover, and 
numerous MRS studies have demonstrated that choline metabolism is altered in various 
cancers (104). In Paper II, we explored whether tumor choline levels, quantified by in 
vivo MRS, were associated with high-risk features of endometrial cancer. Additionally, 
we compared choline levels in tumor tissue and the adjacent normal myometrium. The 
ratios tCho/Creatine, tCho/Water and tCho/Noise were consistently higher in tumor 
tissue than in normal myometrium. In line with this, previous studies have reported that 
MRS tCho quantifications can differentiate endometrial cancers from benign lesions 
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(60-62). Also, in vitro studies have shown that the choline-metabolite profile in cancer 
tissue is highly different from that observed in normal or benign tissue (105-107). Our 
study also showed that high tumor tCho/Water ratio was significantly associated with 
high tumor grade in endometrioid tumors (p=0.02, Jonckheere-Terpstra trend test). 
However, none of the tCho ratios could differentiate non-endometrioid from 
endometrioid tumors, and when analyzing all tumors together, high tCho/Water only 
tended (p=0.08, Mann-Whitney U test) to predict high-risk histological subtype 
(endometrioid grade 3 or non-endometrioid). Zhang et al. also found no significant 
association between tCho/Water and tumor grade in 38 endometrial cancer patients 
(61) and Han et al. reported no significant association between tCho/Noise and tumor 
grade in 33 endometrial cancer patients (62). 
 
Considering that our study also did not find significant predictors of deep 
myometrial invasion, cervical stroma invasion, lymph node metastases or recurrence- 
and progression-free survival, the immediate clinical value of MRS, at present, seems 
somewhat limited. On the other hand, the method is clearly able to extract tumor-
specific metabolic information, and with methodological refinements it may potentially 
aid in preoperative risk stratification. Relatively small patient cohorts and somewhat 
heterogeneous approaches in currently available publications imply that definite 
conclusions may not be drawn.  
 
6.2.4 Texture analysis of MRI and CT 
In Paper III and IV, we have demonstrated that texture features extracted from 
preoperative MRI and CT are significantly associated with high-risk disease and poor 
outcome in endometrial cancer. In multivariable analyses including endometrial biopsy 
status, conventional MRI reading results and tumor volume (estimated by MRI), the 
texture features remained significant and independent predictors of deep myometrial 
invasion, cervical stroma invasion, high-risk histological subtype and 
recurrence/progression-free survival (Table 5 and 6). Our findings are in line with other 
endometrial cancer studies also reporting image texture features as predictors of high-
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risk disease (68, 69) – although not being directly comparable. In a broader context, 
our results also support a more general hypothesis stating that tumor heterogeneity, 
whether at the genetic, histological or macroscopic level, may reflect tumor 
aggressiveness (67). In recent years, with the introduction of radiomics, a shift towards 
computer-assisted extraction of quantitative features from radiological imaging data, 
rather than the traditional subjective assessments and simple measurements, has 
emerged. A review article from 2016 with the illustrative title “Images are more than 
pictures, they are data” elaborates on this topic (99). Numerous publications have 
reported image texture analysis as a promising tool in the diagnostic workup in several 
cancer types (70-73, 108-110), i.e. supporting accurate diagnosis, preoperative risk 
stratification or assessment of treatment response. 
High entropy in ADC maps (Paper III) and high entropy in ceCT (Paper IV) 
were the highest ranked predictors of deep myometrial invasion in the respective 
studies (Table 5). Furthermore, high entropy in ceCT also independently predicted 
cervical stroma invasion (Paper IV). High kurtosis in T1c images (Paper III) and high 
kurtosis in ceCT (Paper IV) were the highest ranked prognostic features in the 




Table 5. Uni- and multivariable logistic regression for prediction of deep myometrial 
invasion, cervical stroma invasion, lymph node metastases and high-risk histological 
subtype at surgical staging from MRI- and CT derived tumor texture parameters. 
    
Univariable Multivariable 
 Tumor texture 
parameters 
n Unadjusted OR 
(95% CI) 









ADC_Entropy6 175 4.7 (2.8-7.8) <0.001 3.2 (1.7-6.1)a <0.001a 
ceCT_Entropy6 153 6.7 (2.8-16.0) <0.001 3.7 (1.4-9.7)b 0.008b 
Predictor with cutoffg      
ADC_Entropy6 ≥4.49 69/175 12.0 (5.8-24.7) <0.001 6.2 (2.5-15.1)a <0.001a 
ceCT_Entropy6 ≥4.84 71/153 3.9 (2.0-7.7) <0.001 2.4 (1.1-5.2)b 0.02b 




T2_MPP4 178 0.995 (0.99-1.00) 0.03 0.996 (0.99-1.00)c 0.11c 
ceCT_Entropy6 153 4.4 (1.5-12.8) 0.006 3.9 (1.2-12.4)d 0.02d 
Predictor with cutoffg      
T2_MPP4 <137 49/178 4.0 (1.8-9.0) <0.001 3.6 (1.5-8.7)c 0.005c 
ceCT_Entropy6 ≥4.85 68/153 4.6 (1.8-11.8) 0.001 4.5 (1.6-12.6)d 0.004d 
       
Lymph node 
metastases 
T1c_Entropy6 154 3.1 (1.5-6.6) 0.003 1.7 (0.7-4.3)a 0.26a 
ceCT_Kurtosis5 131 1.3 (1.1-1.7) 0.01 1.1 (0.8-1.5)b 0.75b 
Predictor with cutoffg      
T1c_Entropy6 >5.31 49/154 6.0 (2.1-16.9) <0.001 2.6 (0.7-9.9)a 0.16a 
ceCT_Kurtosis5 >0.16 61/131 6.0 (1.6-22.4) 0.007 3.4 (0.8-14.0)b 0.09b 




T1c_MPP4 178 1.01 (1.00-1.01) 0.001 1.01 (1.00-1.01)e 0.004e 
ceCT_MPP5 153 1.01 (1.00-1.03) 0.02 1.01 (1.00-1.03)f 0.10f 
Predictor with cutoffg      
T1c_MPP4 >123 80/178 3.1 (1.6-5.7) <0.001 3.9 (1.7-9.4)e 0.002e 
ceCT_MPP5 >24.2 96/153 4.7 (2.2-10.2) <0.001 3.7 (1.3-10.1)f 0.01f 
       
a Adjusted for MRI-measured tumor volume, conventional MRI reading and biopsy risk statush. 
b Adjusted for MRI-measured tumor volume, conventional MRI reading, age and biopsy risk statush. 
c Adjusted for MRI-measured tumor volume, conventional MRI reading and cervical tumor involvement status in 
the preoperative endocervical curettage. 
d Adjusted for MRI-measured tumor volume, conventional MRI reading, age and cervical tumor involvement status 
in the preoperative endocervical curettage. 
e Adjusted for MRI-measured tumor volume and biopsy risk statush. 
f Adjusted for MRI-measured tumor volume, age and biopsy risk statush. 
g Cutoffs are determined by ROC curve analysis selecting the highest Youden index. 
h High-risk histological subtype is defined as endometrioid grade 3 or non-endometrioid subtype as opposed to low-
risk histological subtype defined as endometrioid grade 1 and 2. 
 
Texture features are annotated with number indicating spatial scale filter (SSF). 
 
ADC, apparent diffusion coefficient (map); ceCT, contrast-enhanced CT; CI, confidence interval; CT, computed 





Table 6. Uni- and multivariable Cox regression analysis for prediction of recurrence- 
and progression-free survival in endometrial cancer. 
    
Univariable Multivariable 
Outcome Predictor n Unadjusted HR 
(95% CI) 





      
RPFS 
(Paper III) 
T1c_Kurtosis2 180 1.7 (1.3-2.3) <0.001 1.5 (1.2-2.0) <0.001 
MRI tumor volume 180 1.01 (1.00-1.01) <0.001 1.01 (1.00-1.01) 0.007 
High-risk biopsyb 177 4.3 (2.3-8.0) <0.001 3.4 (1.8-6.4) <0.001 
Predictor with cutoffc      
T1c_Kurtosis2 ≥0.26 91/180 3.2 (1.6-6.4) <0.001 2.2 (1.1-4.5) 0.03 
       
RPFS 
(Paper IV) 
ceCT_Kurtosis5 155 1.2 (1.1-1.2) <0.001 1.1 (1.0-1.2) 0.06 
MRI tumor volume 155 1.01 (1.00-1.01) <0.001 1.01 (1.00-1.01) 0.01 
High-risk biopsya 152 3.6 (1.9-6.9) <0.001 2.6 (1.3-5.2) 0.01 
Age 155 1.03 (1.00-1.07) 0.06 1.02 (0.98-1.05) 0.33 
Predictor with cutoffc      
ceCT_Kurtosis5 ≥1.00 39/155 2.9 (1.5-5.5) 0.002 1.8 (0.9-3.8) 0.10 
       
a All variables grouped by vertical leaders are included in each multivariable analysis. (When analyzing texture 
variables with cutoff, the continuous variable is replaced by the corresponding categorical variable in the same 
analysis.) 
b High-risk biopsy is defined as endometrioid grade 3 or non-endometrioid subtype as opposed to low-risk 
comprising endometrioid grade 1 and 2. 
c Cutoffs are determined by Kaplan-Meier analyses, in which consecutive groups (quartiles) with similar survival 
are merged: For T1c_Kurtosis2 the median value was selected as cutoff, and for ceCT_Kurtosis5 the 75-percentile 
value was selected as cutoff. 
 
Texture features are annotated with number indicating spatial scale filter (SSF). 
 
ceCT, contrast-enhanced computed tomography; CI, confidence interval; HR, hazard ratio; MRI, magnetic 
resonance imaging; RPFS, recurrence- and progression-free survival; T1c, contrast-enhanced T1-weighted 
(images). 
 
Entropy is a measure of random irregularity and kurtosis is related to the 
peakedness of the pixel distribution curve in ROIs. In general, high entropy and high 
kurtosis in tumor images reflect increased histological heterogeneity (71), which in turn 
is often related to irregular tissue architecture induced by tumor-induced angiogenesis, 
hypoxia and necrosis (111). Thus, our findings support that intratumor heterogeneity 
is associated with tumor aggressiveness and reduced survival, which is also reported in 
several pan-cancer studies assessing genetic heterogeneity in a variety of cancer types 
(112, 113). In Paper III, high MPP in T1c images independently predicted high-risk 
histological subtype (Table 5), and in Paper IV, MPP>24.2 also independently 
predicted high-risk histological subtype (Table 5). MPP is a TexRAD specific feature 
defined as the mean value of positive pixels. In CT images MPP can be calculated from 
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unfiltered as well as filtered images. In MRI, however, the feature MPP is relevant only 
in filtered images (as native MR images have no negative pixel values), i.e. when 
objects of a given size in the images are enhanced, by which pixels are recoded into a 
range of positive values or negative values according to their native values, as 
elaborated in a review by Miles et al. (98). Consequently, MPP is a measurement of 
brightness in the highlighted objects in the ROIs, and the impact of dark objects in the 
ROIs (e.g. nonenhancing fluid collections in T1c images) is reduced. In a study of non-
small cell lung cancer, Ganeshan et al. (72) found significant associations between 
MPP in ceCT tumor ROIs and histological markers of tumor hypoxia and angiogenesis. 
A recent study of pancreatic cancer also found MPP in ceCT tumor ROIs to be 
significantly associated with overall survival (71). In the only previous study on MRTA 
in endometrial cancer, Ueno et al. included MPP of DCE images and ADC maps among 
10 other texture features in the prediction of lymphovascular space invasion (68). 
Although inherently dependent on the imaging modality and sequence, and even if the 
biological correlate of MPP is somewhat unclear, it seems to have a potential as an 
imaging biomarker, which our findings also support. 
In current literature, most studies on image texture analysis have relatively small 
patient numbers, and are typically retrospective and could be regarded as proof-of-
principle studies. The need for further validation of texture features as imaging 
biomarkers is obvious. To potentially increase the clinical applicability of texture 
features, we also suggest aiming at developing more integrative risk prediction models, 
tentatively including elements from different imaging modalities as well as other 
biomarkers available preoperatively (e.g. histological and molecular biopsy markers, 
serum markers and relevant clinical information). Eventually, prospective studies with 
a priori cutoff values of the included biomarkers should be undertaken. 
 
6.2.5 Diagnostic performance of imaging markers and their prognostic value 
For prediction of deep myometrial invasion and lymph node metastases, we 
have summarized the diagnostic performance of relevant imaging markers in Paper I-
IV in Table 7. ROC curve analyses in the respective cohorts show that markers based 
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on tumor size measurements on conventional MR images (Paper I) and texture 
features from MR images (Paper III) have the highest AUC for prediction of DMI as 
well as LNM. MR spectroscopy-based markers (Paper II) have the lowest AUC in 
both analyses. In this context, it should be mentioned that these AUC values do not 
give information regarding the predictors’ independency from established risk factors. 
 
For prediction of recurrence- and progression-free survival (Table 8), MRI-
measured tumor size (Paper I) and texture features derived from MRI and CT (Paper 
III and IV) are clearly more interesting imaging markers than those derived from MR 
spectroscopy (Paper II). Choline levels in tumor (as measured by the ratios 
tCho/Creatine, tCho/Water and tCho/Noise) do not seem to reflect survival, whereas 
the highest ranked size and texture features yield HRs around 3 (unadjusted) when 
appropriate cutoffs are applied. 
 
Methodologically, among the image derived markers explored in this thesis, 
tumor size measurement on MR images would probably, at present, be the most 
feasible marker in daily radiological practice. Interestingly, these markers are also 
among the highest ranked for prediction of high-risk disease and poor outcome (Table 
7 and 8), and they are proven highly reliable (Paper I). 
 
Although our studies were not designed for head-to-head comparison of MRI 
versus CT, it seems reasonable to infer that, in general, MRI texture features are more 
strongly associated with high-risk endometrial cancer including poor outcome, than CT 
texture features (Table 6-8). However, if MRI is unavailable, it is worth noting that 
texture analysis of ordinary diagnostic CT images may provide added value in the 
preoperative risk stratification.  
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Table 7. Diagnostic performance of imaging markers for prediction of deep 
myometrial invasion and lymph node metastases. 
 
  Deep myometrial invasion 
 
 
Paper Method Predictor n AUC 
 
I MRI AP tumor diameter 212 0.82 
 I MRI Tumor volume 212 0.81 
 I MRI TV tumor diameter 212 0.78 
 I MRI CC tumor diameter 212 0.76 
 II MRS Tumor tCho/Noise 77 0.61 
 II MRS Tumor tCho/Creatine 75 0.59 
 II MRS Tumor tCho/Water 77 0.56 
 III MRTA Tumor ADC_Entropy6 175 0.81 
 III MRTA Tumor T1c_Entropy0 178 0.80 
 IV CTTA Tumor ceCT_Entropy6 153 0.71 
 IV CTTA Tumor ceCT_Kurtosis3 153 0.71 
 
  Lymph node metastases 
 
I MRI CC tumor diameter 181 0.76 
 I MRI Tumor volume 181 0.70 
 I MRI AP tumor diameter 181 0.68 
 I MRI TV tumor diameter 181 0.67 
 II MRS Tumor tCho/Noise 70 0.61 
 II MRS Tumor tCho/Creatine 68 0.61 
 II MRS Tumor tCho/Water 70 0.49 
 III MRTA Tumor T1c_Entropy6 154 0.73 
 III MRTA Tumor ADC_Entropy0 151 0.71 
 IV CTTA Tumor ceCT_Kurtosis5 131 0.69 
 IV CTTA Tumor ceCT_Entropy2 131 0.66 
      
Texture features are annotated with number indicating spatial scale filter (SSF). 
ADC, apparent diffusion coefficient (map); AP, anteroposterior; AUC, area under curve (i.e. receiver operator characteristic curve); 
CC, craniocaudal; ceCT, contrast-enhanced CT; CT, computed tomography; CTTA, CT texture analysis; MRI, magnetic resonance 
imaging; MRS, MR spectroscopy; MRTA, MR texture analysis; T1c, contrast-enhanced T1-weigted (images); tCho, total choline 
containing metabolites; TV, transverse. 
 
 66
Table 8. Prognostic value of imaging markers based on univariable Cox regression 
analysis. 
 
  Recurrence- and progression-free survival 
 
 
Paper Method Predictor n HR p 
 
I MRI AP tumor diameter (mm) 212 1.04 <0.001 
 I MRI CC tumor diameter (mm) 212 1.03 <0.001 
 II MRS Tumor tCho/Noise 77 1.14 0.33 
 II MRS Tumor tCho/Creatine 75 0.99 0.84 
 II MRS Tumor tCho/Water 77 0.93 0.49 
 III MRTA Tumor T1c_Kurtosis2 180 1.7 <0.001 
 III MRTA Tumor ADC_Entropy6 177 2.0 <0.001 
 III MRTA Tumor T1c_Entropy6 180 2.1 <0.001 
 IV CTTA Tumor ceCT_Kurtosis5 155 1.2 <0.001 
 
Paper Method Predictor with cutoff* proportion HR p 
 
I MRI AP diameter > 20 mm 72/212 2.9 <0.001 
 I MRI CC diameter > 40 mm 69/212 2.4 0.005 
 I MRI AP > 20 mm and CC > 40 mm 52/212 3.4 <0.001 
 II MRS No significant predictor - - - 
 III MRTA T1c_Kurtosis2 ≥ median 91/180 3.2 <0.001 
 III MRTA ADC_Entropy6 ≥ median 89/177 2.5 0.005 
 III MRTA T1c_Entropy6 ≥ 75-percentile 45/180 3.0 <0.001 
 IV CTTA ceCT_Kurtosis5 ≥ 75-percentile 39/155 2.9 0.002 
       
*Cutoffs for tumor size are based on highest possible Youden index for prediction of deep myometrial invasion and lymph node 
metastases, respectively. Cutoffs for tumor texture features are based on Kaplan-Meier analyses, in which consecutive groups 
(quartiles) with similar survival are merged. 
Texture features are annotated with number indicating spatial scale filter (SSF). 
ADC, apparent diffusion coefficient (map); AP, anteroposterior; CC, craniocaudal; ceCT, contrast-enhanced CT; CT, computed 
tomography; CTTA, CT texture analysis; HR, hazard ratio; MRI, magnetic resonance imaging; MRS, MR spectroscopy; MRTA, 





Tumor size can be measured on preoperative conventional MRI with very low 
interobserver variability. Large tumor size predicts deep myometrial invasion, lymph 
node metastases and poor outcome in endometrial cancer. Using the cutoff values AP 
diameter >2 cm and CC diameter >4 cm may improve preoperative risk stratification 
(Paper I). 
 
High choline levels, as measured by preoperative in vivo 1H-MR spectroscopy, 
differentiates tumor tissue from normal tissue in endometrial cancer patients. In 
endometrioid tumors, tCho/Water ratio increases with higher histological grade. 
tCho/Creatine ratio is correlated with MRI-measured tumor volume. However, choline 
levels do not seem to be associated with recurrence- and progression-free survival 
(Paper II). 
 
MRI-derived tumor texture parameters predict deep myometrial invasion, high-
risk histological subtype, and reduced recurrence- and progression-free survival in 
endometrial cancer (Paper III). CT-derived tumor texture features predict deep 
myometrial invasion and cervical stroma invasion in endometrial cancer, and also tend 
to predict high-risk histological subtype and survival (Paper IV). The image texture 
features entropy, kurtosis and MPP seem to reflect tumor heterogeneity and may serve 
as supplementary imaging biomarkers for more refined preoperative risk assessment 
that may ultimately enable better tailored treatment strategies in endometrial cancer 




8 Future perspectives 
 
The studies in this thesis have aimed at identifying robust and accurate imaging 
biomarkers that may aid in the preoperative staging and risk stratification in 
endometrial cancer. The explored imaging features have all been quantitative in nature. 
The proposed tumor size cutoffs (Paper I) for identification of high-risk endometrial 
cancer, were a posteriori applied and optimized for the current dataset, which is 
adequate as an initial study. Given the promising results in Paper I, a future validation 
study with tumor size cutoffs a priori defined for an independent cohort, would be very 
interesting. The idea of replacing MRI-based depth-of-myometrial-invasion scoring 
with tumor size measurement could also be pursued. With recent advances of 
ultrasound technology, updated head-to-head studies comparing TVUS and MRI in 
terms of tumor size measurements and tumor invasion assessments, would also be 
interesting. 
 
The paucity of significant findings in Paper II might discourage future research 
on MR spectroscopy in endometrial cancer. Still, the method is indisputably intriguing, 
as it – at least theoretically – has the potential to reveal a metabolic tumor profile, which 
eventually may become relevant in future targeted therapies. It is worth mentioning 
that all currently available studies on MR spectroscopy in endometrial cancer, 
including our study, are relatively small. A larger study at 3T (or higher field) with 
exploration of a wider range of metabolites (not limited to choline as in our study) 
would definitely be interesting – especially if methodological refinements could help 
to overcome some of the obstacles of spectroscopic imaging of the uterus in vivo. 
 
Image texture analysis is largely unexplored in endometrial cancer. The promising 
results of MR- and CT texture analysis in Paper III and IV, accompanied by a few 
other endometrial cancer studies reporting texture analysis of MRI (68) and PET (69) 
as promising tools for preoperative risk stratification, should encourage future studies 
in this field. Our findings need validation across observers, institutions and software 
platforms. In general, texture analysis can be considered as one out of many elements 
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of radiomics, the science of high-throughput extraction of quantitative features from 
radiological imaging data. Future perspectives of radiomics include machine learning, 
and probably also approaches related to artificial intelligence. Our annotated 
endometrial cancer dataset (including clinical, imaging, histological and molecular 
data) is well suited for further radiomic studies. During recent years we also have 
examined a substantial number of endometrial cancer patients at 3T MRI. With 
increased image quality, the potential for texture analysis might also be increased. 
Eventually, some degree of standardization is needed to establish image texture 
analysis as a risk stratification tool in a true prospective setting and in clinical practice. 
Development of future risk stratification models would probably also benefit from a 
more multimodal and integrative approach, not limiting models to imaging markers. 
Thus, multidisciplinary research with radiology playing a key role, will hopefully yield 
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Preoperative Tumor Size at MRI Predicts Deep
Myometrial Invasion, Lymph Node Metastases,
and Patient Outcome in Endometrial Carcinomas
Sigmund Ytre-Hauge, MD,*Þ Jenny A. Husby, MD,*Þ Inger J. Magnussen, MD,*
Henrica M.J. Werner, MD, PhD,þ§ Øyvind O. Salvesen, MSc, PhD,|| Line Bjørge, MD, PhD,þ§
Jone Trovik, MD, PhD,þ§ Ingunn M. Stefansson, MD, PhD,¶# Helga B. Salvesen, MD, PhD,þ§
and Ingfrid S. Haldorsen, MD, PhD*Þ
Objective: The aim of this study was to explore the relation between preoperative tumor
size based on magnetic resonance imaging (MRI) and the surgical pathologic staging pa-
rameters (deep myometrial invasion, cervical stroma invasion, and metastatic lymph nodes)
and to assess the prognostic impact of tumor size in endometrial carcinomas. Interobserver
variability for the different tumor size measurements was also assessed.
Methods/Materials: Preoperative pelvic MRI of 212 patients with histologically con-
firmed endometrial carcinomas was read independently by 3 radiologists. Maximum tumor
diameters were measured in 3 orthogonal planes (anteroposterior, transverse, and
craniocaudal planes [CC]), and tumor volumes were estimated. Tumor size was analyzed in
relation to surgical staging results and patient survival. The multivariate analyses were
adjusted for preoperative risk status based on endometrial biopsy. Intraclass correlation
coefficients and receiver operating characteristics curves for the different tumor measure-
ments were also calculated.
Results: Anteroposterior tumor diameter independently predicted deep myometrial inva-
sion (P G 0.001), whereas CC tumor diameter tended to independently predict lymph node
metastases (P = 0.06). Based on receiver operating characteristic curves, the following
tumor size cutoff values were identified: anteroposterior diameter greater than 2 cm pre-
dicted deep myometrial invasion (unadjusted odds ratio [OR], 12.4; P G 0.001; adjusted OR,
6.7; P G 0.001) and CC diameter greater than 4 cm predicted lymph node metastases
(unadjusted OR, 6.2; P G 0.001; adjusted OR, 4.9; P = 0.009). Large tumor size was as-
sociated with reduced progression/recurrence-free survival (P e 0.005 for all size
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parameters), and CC diameter had an independent impact on survival (adjusted hazards
ratio, 1.04; P = 0.009). The interobserver variability for the different size measurements was
very low (intraclass correlation coefficient, 0.78Y0.85).
Conclusions: Anteroposterior tumor diameter greater than 2 cm predicts deep myometrial
invasion, and CC tumor diameter greater than 4 cm predicts lymph node metastases. Tumor
size is a strong prognostic factor in endometrial carcinomas. Preoperative tumor mea-
surements based on MRI may potentially improve preoperative risk stratification models
and thus enable better tailored surgical treatment in endometrial cancer.
Key Words: Endometrial carcinoma, Tumor size, Magnetic resonance imaging,
Prognosis
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Endometrial cancer is the most common gynecologic ma-lignancy in industrialized countries, and the incidence is
increasing.1 Surgical treatment is planned based on preop-
erative assessment of histological subtype, grade, and depth
of myometrial invasion. Surgical International Federation of
Gynecology and Obstetrics (FIGO) stage is documented to be
the strongest prognostic factor in endometrial carcinoma, thus
guiding adjuvant therapy in addition to the assessment of his-
tologic subtype and grade in the hysterectomy specimen.1Y3
Magnetic resonance imaging (MRI) has long been con-
sidered the diagnostic imaging method of choice for preoper-
ative staging of endometrial carcinomas.4Y6 The presence of
deepmyometrial invasion and cervical stroma invasion could be
visualized, and enlarged lymph nodes could be detected.
However, conventional pelvicMRIhas reportedly limitations in
accuracy in the detection of the staging parameters, in particular
for detecting lymph node metastases.6,7 Interobserver variation
between radiologists for all staging parameters also represents a
source of inaccuracy.8
As opposed to the cervical cancer FIGO staging system,6
FIGO staging for endometrial cancers does not include tumor
size measurements. Nevertheless, large macroscopic tumor
size, assessed in the hysterectomy specimen, has long been
known to predict lymph node metastasis and poor survival in
patients with endometrial carcinomas.9Y13 Recent publications
support that tumor volume based on preoperativeMRI predicts
lymph node metastases and has prognostic impact in endo-
metrial cancer.14,15 However, the reproducibility of MRI-based
tumor measurements has, to our knowledge, not yet been ex-
plored. Furthermore, the optimal cutoff value for risk assess-
ment based on tumor size is not yet defined.
The primary objective of this study was to explore the
relationship between different preoperative tumor size mea-
surements using MRI and the surgical pathologic staging
parameters deep myometrial invasion, cervical stroma inva-
sion, and metastatic lymph nodes in endometrial carcinoma
patients. The secondary objectives were to assess the inter-
observer variability for the different tumor measurements and
to explore the value of these preoperative tumor size mea-
surements to identify patients with poor outcome.
MATERIALS AND METHODS
Patient Series, Study Setting,
and Clinical Outcome
This prospective study was conducted under institu-
tional review boardYapproved protocols with informed con-
sent from all patients. From April 2009 to November 2013,
preoperative pelvic MRI was performed in 212 patients in
whom the diagnosis of endometrial carcinoma was histo-
logically verified at surgical staging. All patients were diag-
nosed and treated at the same university hospital serving a
population of ~1 million inhabitants.
Follow-up data regarding recurrence, progression, and
survival have been collected from patient records and from
correspondence with the responsible primary physicians or
gynecologists. The date of the last follow-upwas July 2014, and
themean (range) follow-up for survivorswas25 (0Y58)months.
Histological Diagnosis
All patients were surgically staged according to the 2009
FIGO staging criteria.2 The responsible surgeon decided the
extent of sampling, balancing preoperatively known histologic
risk factors and the patient’s comorbidity. The patient group
without lymph node sampling is typically older with more
myometrial invasion, otherwise not different from the sampled
group.16 Surgical specimens were sectioned along the longi-
tudinal plane of the uterus, and myometrial invasion and cer-
vical stromal invasion were estimated grossly and confirmed
microscopically according to standard procedures.17 Routine
histopathology reports were generated without knowledge of
preoperative MRI findings. The pathologists documented
number and size of metastatic lymph nodes.
MRI Protocol
Contrast-enhanced (CE)MRI was performed on a 1.5-T
SiemensAvantoRunningSyngoMRB17 (Erlangen,Germany)
using a 6-channel body coil8 in accordance with the guidelines
of European Society of Urogenital Imaging.5 Themean (range)
interval between MRI examination and surgical staging was
11.3 (0Y98) days.
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Data Analysis
All images were deidentified and read independently by
3 observers who were blinded for tumor stage, histological
diagnosis, and patient outcome. Observer 1 and 2 are con-
sultants with more than 10 years of experience with pelvic
MRI. Observer 3 included 2 junior radiologists (both having
more than 4 years of experience with pelvic MRI); one read
the first 105 MRI examinations, and the other read the fol-
lowing 111 examinations.
All observers reported imaging findings on a stan-
dardized form. Presence of deep myometrial invasion (tumor
invading half or more of the myometrial wall), cervical stroma
invasion (disruption of the low-signal intensity cervical
stroma on T2-weighted images), and enlarged pelvic or para-
aortic lymph nodes (largest short-axis diameter 910mm)were
recorded. Maximum tumor diameters were measured in 3
orthogonal planes: anteroposterior (AP) and transverse (TV)
diameters on axial CE T1-weighted oblique images (per-
pendicular to the long axis of the uterus) as well as
craniocaudal (CC) diameters on sagittal T2-weighted images
(Fig. 1). Tumor volume was then estimated based on these
measurements of maximum tumor diameter in 3 orthogonal
planes using the following equation: tumor volume = AP
diameter  TV diameter  CC diameter/2.
To establish the overall imaging findings based on the
recordings by all 3 observers, we also computed a new data set
(‘‘consensus reading’’) in which the value given by the ma-
jority of the observers was recorded for categorical variables,
and the median value was recorded for continuous variables.
Statistical Analysis
Estimation of sample size was done by W2 test using
software East4 2005 (Cytel Software Corp). To achieve 90%
power of detecting a 20% higher occurrence of positive
markers in patients with metastatic lymph nodes (5% vs 25%)
at a 5% significance level, 101 patients were needed for in-
clusion, defining the minimum number of patients to be in-
cluded in theMRI study. To reach 90% power detecting a 30%
difference in 5-year survival (90% for patients with markers
within reference range vs 60% with pathologic markers) at a
5% level of significance, 65 patients were needed, assuming a
positive to negative ratio of the markers of 1:3.
Clinical and histopathology staging parameters were
analyzed in relation to tumor size measurements using Mann-
Whitney U test, Kruskal-Wallis H test, Jonckheere-Terpsta
trend test, W2 test, and binary logistic regression analysis.
Intraclass correlation coefficient was used to assess the
consistency and reproducibility of tumor size measurements,
and minimal detectable change (1.96  standard error of the
mean square root of 2) for the measured diameters was also
calculated.
Receiver operating characteristic (ROC) analysis was
performed to evaluate the diagnostic value of the different
tumor size measurements in identifying deep myometrial
invasion, cervical stroma invasion, and lymph node metas-
tases. The optimal cutoff values (rounded to centimeters) were
determined for which the best separation in Youden index
between groups was achieved.
Differences in time to recurrence (for patients consid-
ered cured by primary treatment) or progression (for patients
known to have residual disease after primary treatment) were
assessed by the Mantel-Cox (log-rank) linear trend test. The
Cox proportional hazards model was used to study the effect
on survival of continuous variables. The prognostic value of
different tumor size categories was explored with univariate
analyses using Kaplan-Meier, and groups with similar sur-
vival were merged. McNemar test was used for pairwise
analysis for differences in sensitivity, specificity, and accu-
racy. The data were analyzed using SPSS 22.0 (Chicago, IL)
and Stata 12.1 (College Station, TX). All reported P values
were 2-sided and considered to indicate statistical signifi-
cance when less than 0.05.
RESULTS
Patients
The median (mean) patient age in the study sample
(n = 212) was 66 (66) years (range, 32-93), and 91% (193/212)
of the patients were postmenopausal. Applying the FIGO
2009 staging criteria, 55% (116/212) were stage IA (G50%
FIGURE 1. Axial oblique CE T1-weighted image (A) and sagittal T2-weighted image (B) for measurements of
maximum tumor diameters in 3 orthogonal planes. AP and maximum TV diameters were measured on the axial
oblique image (A), whereas CC diameters were measured on the sagittal image (B).
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myometrial invasion), 23% (48/212) stage IB (Q50% myo-
metrial invasion), 11% (23/212) stage II (cervical stroma
invasion), 11% (24/212) stage III (local or regional tumor
spread), and 0% (1/212) stage IV. The histological subtype
was endometrioid in 81% (171/212) of which 50% (86/171)
were grade 1, 29% (50/171) grade 2, and 17% (29/171) grade
3; whereas 4% (6/171) were ungraded. Clear cell histology
was detected in 3% (6/212), serous in 10% (21/212), carci-
nosarcoma in 4% (9/212), and undifferentiated in 2% (5/212).
Metastatic lymph nodes were more frequent in patients with
deep myometrial invasion, cervical stroma invasion, high his-
tologic grade, aneuploidy, and body mass index (BMI) greater
than 25 (Table 1).
All patientswere primarily treatedwith hysterectomy and
bilateral salpingo-oophorectomy. Pelvic lymph node sampling
was performed in 85% (181/212) as part of the routine surgical
staging procedure. Adjuvant therapy was given to 33% (70/
212), chemotherapy in 28% (59/212), pelvic radiation in 5%
(10/212), and hormonal treatment in 0% (1/212).
Tumor Size Is Correlated to
Surgicopathologic Findings
The mean (median, range) preoperative tumor di-
ameters were 28 (26, 0Y113) mm for axial TV diameter, 18
(16, 0Y77) mm for axial AP diameter, and 35 (31, 0Y102) mm
for sagittal CC diameter. The mean (median, range) estimated
tumor volume was 19 (6, 0Y444) mL. Tumor volume was
significantly higher in patients with deep myometrial inva-
sion, cervical stroma invasion, and lymph node metastases at
surgical staging and in patients with aneuploidy and high
histologic grade (Table 2).
Tumor measurements in the 3 orthogonal planes and
tumor volume did all predict the presence of deep myometrial
invasion at surgical staging (unadjusted odds ratios [ORs],
1.06Y1.13; P G 0.001 for all); however, AP tumor diameter
was the only size variable independently predicting deep
myometrial invasion (adjusted OR, 1.14; P G 0.001).
Craniocaudal tumor diameter was the only variable predicting
cervical stroma invasion (adjusted OR, 1.04; P = 0.008).
Although all size parameters predicted lymph node metas-
tases in the univariate analyses (unadjusted ORs, 1.02Y1.05;
P e 0.004 for all), only CC tumor diameter tended to inde-
pendently predict lymph node metastases (adjusted OR, 1.04;
P = 0.06).
Receiver operator characteristic curves for the different
size parameters in the prediction of deep myometrial invasion
(Fig. 2A), cervical stroma invasion (Fig. 2B), and lymph node
metastases (Fig. 2C) showed that AP diameter had the highest
area under the curve (AUC, 0.82) for deepmyometrial invasion,
whereas CC diameter had the highest AUC for cervical stroma
invasion (AUC, 0.66) and for lymph node metastases (AUC,
0.76). Based on these ROC curves, the following cutoff values
were identified: AP tumor diameter greater than 2 cm predicts
deep myometrial invasion yielding sensitivity/specificity of
66%/86% and an OR of 12.4, and CC tumor diameter greater
than 4 cm predicts lymph node metastases yielding sensitivity/
specificity of 70%/73% and an OR of 6.2, whereas CC tumor
diameter greater than 3 cm tends to predict cervical stroma
invasion yielding sensitivity/specificity of 66%/51% and an
TABLE 1. Clinical characteristics and MRI findings in
relation to the presence of metastatic lymph nodes at




n = 20 n = 161
n (%) n (%)
Low-risk group† 72 0 (0) 72 (46) G0.001
Intermediate-risk group† 51 10 (50) 41 (26)
High-risk group† 54 10 (50) 44 (28)
Myometrial invasion G 0.001
G50% 109 4 (20) 105 (65)
Q50% 72 16 (80) 56 (35)
Cervical stroma invasion 0.001
Yes 27 8 (40) 19 (12)
No 154 12 (60) 142 (88)
Histologic subtype 0.14
Endometrioid 141 13 (65) 128 (80)




Grade 1 70 2 (15) 68 (55)
Grade 2 42 5 (38) 37 (30)
Grade 3 25 6 (46) 19 (15)
Ploidy 0.014
Diploid 77 6 (50) 71 (82)
Aneuploid 22 6 (50) 16 (18)
Age, y 0.10
G66 95 7 (35) 88 (54)
Q66 86 13 (65) 73 (45)
BMI 0.03
G25 66 3 (15) 63 (40)
Q25 113 17 (85) 96 (60)
Tumor size at MRI G0.001
AP e2 cm and/or
CC e4 cm
136 8 (40) 128 (80)




Enlarged lymph nodes 13 9 (45) 4 (2)
Normal lymph nodes 168 11 (55) 157 (98)
Significant P values are presented in boldface.
*W2 Test.
†Risk groups defined in European Society for Medical Oncology
guidelines26: low risk, endometrioid grade 1/2 with myometrial inva-
sion G50%; intermediate risk, endometrioid grade 1/2withmyometrial
invasion Q50% or endometrioid grade 3 with myometrial invasion G
50%; high risk, endometrioid grade 3 with myometrial invasion Q50%
or nonendometrioid histology
LN+, patients with lymph nodes metastases at surgical staging;
LNj, patients without lymph node metastases at surgical staging.
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OR of 2.0 (Table 3). When adjusting for risk status based on
preoperative endometrial biopsy and for conventional imaging
findings (consensus reading) suggesting deep myometrial
invasion, cervical stroma invasion, and lymph node metasta-
ses, respectively, AP diameter greater than 2 cm independently
predicted deep myometrial invasion (adjusted OR, 6.7), and
CC diameter greater than 4 cm independently predicted lymph
node metastases (adjusted OR, 4.9), whereas CC diameter
greater than 3 cm did not predict cervical stroma invasion
(Table 3).
Tumor Size Predicts Progression/
Recurrence-Free Survival
The 3 tumor diameter measurements and tumor volume
did all predict progression/recurrence-free survival (P e 0.01
for all size parameters) in endometrial carcinoma patients. In a
multivariate analysis including all size parameters and pre-
operative risk status based on endometrial biopsy, only CC
tumor diameter had an independent impact on survival (Table 4,
SupplementalDigital Content, http://links.lww.com/IGC/A270).
When stratifying patient groups according to the proposed
cutoff values for size variables defined by the ROC analyses,
patients with AP tumor diameter greater than 2 cm and patients
with CC tumor diameter greater than 4 cm had significantly
reduced progression/recurrence-free survival (P e 0.03 for
both; Figs. 3A, B). Combining these 2 size criteria yielded
similar survival curves among patients with both or 1 size
criterion below the cutoff values (the 2 survival curves are thus
merged in Fig. 3C), whereas patients with both AP tumor di-
ameter greater than 2 cm and CC tumor diameter greater than
4 cm had significantly reduced progression/recurrence-free
survival (P = 0.004; Fig. 3C).
Interobserver Variability for Tumor
Measurements
The interobserver variability for tumor diameter
measurements by the 3 observers was low with intraclass
correlation coefficients of 0.78 to 0.85 and minimum de-
tectable change of 14 to 26 mm for the different tumor di-
ameter measurements (Table 5, Supplemental Digital Content,
http://links.lww.com/IGC/A270). Furthermore, the AUCvalues
of the ROC curves for prediction of deep myometrial invasion,
cervical stroma invasion, and lymph node metastases were not
significantly different between observers (Figs. 2D-F).
DISCUSSION
In this large population-based study, we demonstrate a
significant predictive value of preoperative tumor size mea-
surements based on MRI to identify deep myometrial invasion
and lymph node metastases. Furthermore, tumor size had a
significant independent impact on survival alsowhen adjusting
for preoperative risk status based on endometrial biopsy. Based
on the present study, we propose a riskmodelwith cutoff values
of AP tumor diameter greater than 2 cm indicating high risk for
deep myometrial invasion and CC tumor diameter greater than
4 cm indicating high risk for lymph node metastases. Having
established that the interobserver variability for these different
tumor measurements at MRI was very low, we infer that these
preoperative tumor measurements with corresponding cutoff
values may represent robust biomarkers aiding in the preop-
erative risk stratification and in planning of tailored surgical
treatment in endometrial cancer patients.
Presence of deep myometrial invasion in hysterectomy
specimen at surgicopathological staging is associated with an
increased risk of lymph node metastases, tumor recurrence,
and distant relapse in endometrial carcinoma patients.3,18 We
found that all size parameters predicted deep myometrial
invasion, which is in accordance with the findings of Todo
et al14 reporting high volume indexes (defined as the product
TABLE 2. Tumor volume in relation to clinical and







G50% 132 7.4 (5.2Y9.7)
Q50% 80 37.5 (23.4Y51.6)
Cervical stroma invasion 0.049
Yes 32 33.7 (5.2Y62.2)
No 180 16.1 (11.4Y20.8)
Lymph node metastases G0.004
Yes 20 62.7 (12.0Y113.5)
No 161 13.9 (10.2Y17.6)
Histologic subtype 0.27
Endometrioid 171 13.4 (10.2Y16.6)
Clear cell 6 20.6 (0.0Y50.4)
Serous 21 21.0 (4.9Y37.1)
Carcinosarcoma 9 65.5 (0.0Y135.8)




Grade 1 86 8.9 (5.6Y12.1)
Grade 2 50 14.7 (9.4Y19.9)
Grade 3 29 26.5 (13.2Y39.8)
Ploidy 0.015
Diploid 91 24.7 (12.8Y36.7)
Aneuploid 23 41.1 (21.4Y60.7)
Age, y 0.21
G66 106 15.6 (7.0Y24.3)
Q66 106 22.0 (14.2Y29.8)
BMI 0.38
G25 74 15.1 (9.1Y21.1)
Q25 134 20.9 (12.4Y29.4)
Significant P values are presented in boldface.
*Mann-WhitneyU test for 2 categories and Kruskal-Wallis H test
or Jonckheere-Terpsta trend test for multiple categories.
CI, confidence interval.
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TABLE 3. Sensitivity, specificity, LR+, LRj, and OR for the prediction of deep myometrial invasion
(by AP tumor diameter 92 cm), cervical stroma invasion (by CC tumor diameter 93 cm), and lymph node
metastases (by CC diameter 94 cm) using surgical staging as the criterion standard
AP Tumor Diameter
92 cm and Deep
Myometrial Invasion
CC Tumor Diameter
93 cm and Cervical
Stroma Invasion
CC Tumor Diameter
94 cm and Lymph
Node Metastases
Sensitivity, % (positive/total no. patients) 66 (53/80) 66 (21/32) 70 (14/20)
Specificity, % (positive/total no. patients) 86 (114/132) 51 (91/180) 73 (117/161)
LR+ 4.9 1.5 2.6
LRj 0.39 0.68 0.41
Unadjusted and adjusted* OR (95% CI);
P value† for deep myometrial invasion/cervical
stroma invasion/lymph node metastases based
on size cutoff values
12.4 (6.3Y24.5) 2.0 (0.9Y4.3) 6.2 (2.2Y17.2)
P G 0.001 P = 0.10 P G 0.001
6.7 (3.1Y14.4) 1.1 (0.4Y2.7) 4.9 (1.5Y15.8)
P G 0.001 P = 0.85 P = 0.009
*Adjusted for risk status based on preoperative endometrial biopsy and conventional imaging findings (consensus reading) suggesting
deep myometrial invasion, cervical stroma invasion, and lymph node metastases, respectively.
†Binary logistic regression analysis.
LR+, likelihood ratio for positive results: LR+ = sensitivity/(1 j specificity); LRj, likelihood ratio for negative results: LRj =
(1 j sensitivity)/specificity.
FIGURE 2. Receiver operator characteristic curves for the various tumor size measurements for identification of (A)
deep myometrial invasion, (B) cervical stroma invasion, and (C) lymph node metastases and ROC curves for the
different observers for (D) AP diameter to predict deep myometrial invasion, (E) CC diameter to predict cervical
stroma invasion, and (F) CC diameter to predict lymph node metastases in patients with endometrial carcinoma.
P values refer to the test of equal AUC values across tumor measurements.
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of maximum AP, TV, and CC tumor diameters at MRI) to be
associated with deep myometrial invasion. As opposed to
Todo et al,14 we have also explored the independent impact of
the different size variables in a multivariate model including
preoperative risk status based on endometrial biopsy. Inter-
estingly, AP diameter, which had the largest AUC (Fig. 2A),
proved to be the only size variable independently predicting
deep myometrial invasion.
Based on the ROC curve, the optimal cutoff value for
prediction of deep myometrial invasion was AP diameter
greater than 2 cm, and AP diameter greater than 2 cm inde-
pendently predicted deep myometrial invasion even when
adjusting for conventional imaging findings (consensus
reading) suggesting the same. Interestingly, we found that
AP diameter greater than 2 cm and MRI indicating deep
myometrial invasion had comparable accuracy (sensitivity,
specificity) for identification of deep myometrial invasion at
surgical staging: 79% (66%, 86%) and 74% (70%, 77%),
respectively, however, with significantly better specificity for
AP diameter greater than 2 cm (86% vs 77%; P = 0.015,
McNemar test). Thus, this relatively simple approach of
measuring AP tumor diameter yields a diagnostic perfor-
mance similar to or slightly better than conventional reading
for prediction of deep myometrial invasion.
Several surgicopathological risk models for prediction
of lymph node metastases have been proposed in endometrial
cancer based on histologic grade, subtype, and tumor ex-
tent,10,19,20 among which 1 model includes tumor greater than
2 cm based on the gross inspection of hysterectomy speci-
men.10 These models are, however, limited by the fact that
they rely on surgicopathological staging results, which are per
definition not available preoperatively.
Tumor diameter greater than 2 cm in macroscopic fresh
tissue has been reported to independently predict lymph node
metastases and survival9; however, the independent impact on
survival of tumor size greater than 2 cm has not been consis-
tently reproduced in the literature.10,13 Based on macroscopic
gross inspection of the cut-up of the uterus, maximum tumor
dimension greater than 3.75 cm was recently reported an in-
dependent predictor of deep myometrial invasion, distant re-
currence, and death.11 Because CC diameter was almost
uniformly the largest tumor diameter in our study, our cutoff
value for CC diameter greater than 4 cm seems to be in linewith
the proposed cutoff value of 3.75 cm. Direct comparison be-
tween tumor diameter measurements in macroscopic fresh tis-
sue and preoperatively based on MRI is, however, difficult due
to the differences in planes eligible for tumormeasurements and
the potential distortion and compression of tumor tissue in vivo
compared with ex vivo. Thus, the optimal cutoff values for
tumor size are not necessarily transferable from in vivo MRI-
based assessment to the ex vivo gross section-based tumor
measurements. Still, the metastatic potential and unfavorable
prognostic impact of large tumor size in endometrial carcinomas
is consistently supported by both invivo and ex vivo studies.9Y15
We found that the MRI-based parameters AP tumor
diameter greater than 2 cm and CC tumor diameter greater
than 4 cm both alone and combined are strongly associated
with reduced progression/recurrence-free survival in endo-
metrial carcinomas (Fig. 3). These tumor size parameters
should in the future also be evaluated in relation to other
preoperative biomarkers such as p53, hormone receptor, and
DNA ploidy status in preoperative biopsies, prognostic
markers assessed in blood samples,21 and on functional im-
aging by MRI or PET/CT, which have been shown to yield
prognostic information.16,22Y25
For all risk stratification models, high accuracy and
reproducibility of the variables included in the model are
essential. To our knowledge, this is the first study assessing
the interobserver variability for the different tumor size
measurements at MRI in endometrial cancer. Interestingly, we
found that tumor size was measured with very low inter-
observer variability and with no striking difference related to
the readers’ previous experience. Thus, tumor size measure-
ments seem to represent robust biomarkers that are promising
for potential inclusion in future risk stratification models in
endometrial cancer.
FIGURE 3. Kaplan-Meier survival curves depicting progression/recurrence-free survival according to (A) maximal
AP tumor diameter (e2 vs 92 cm), (B) maximal CC tumor diameter (e4 vs 94 cm), and (C) a combination of AP
and CC tumor diameters (AP e2 cm and/or CC e4 cm vs AP 92 cm and CC 94 cm). P values refer to the log-rank
test for equality of survival distribution.
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This study has some limitations. First, the study was
conducted in a single institution using a standardized imaging
protocol. Thus, the potential impact of various imaging pro-
tocols on MRI-based tumor size measurements has not been
assessed. However, our imaging protocol is based on the
guidelines of the European Society of Urogenital Imaging and is
thus expected to be quite similar to those applied at most centers
treating endometrial cancer patients. Second, intraobserver
variability was not assessed in this study. This is, however,
expected to be lower than the observed interobserver variability,
which was very low in this study, and the intraobserver vari-
ability is thus expected to be almost negligible.
In summary, tumor size assessed preoperatively byMRI
predicts the presence of deep myometrial invasion and lymph
node metastases and is a strong prognostic factor in endo-
metrial carcinoma. Based on our findings, we propose cutoff
values greater than 2 cm AP tumor diameter for predicting
deep myometrial invasion and greater than 4 cm CC tumor
diameter for predicting lymph node metastases, as well as
poor survival for the combination of greater than 2 cmAP and
greater than 4 cm CC tumor diameter. Preoperative tumor
measurements at MRI may thus provide clinically relevant
biomarkers for future risk stratification models guiding tai-
lored surgical treatment in endometrial cancer.
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Table 4 (Suppl) 
Unadjusted and adjusted hazard ratios for preoperative tumor size measurements at MRI and 
for preoperative endometrial biopsy suggesting high-risk* for the prediction of 
progression/recurrence-free survival in endometrial carcinomas  
     
     
     
 Tumor size at MRI  
      


















     
     
     
 Unadjusted HR 

















 Adjusted HR 

















     
     
* Preoperative endometrial biopsy indicating non-endometrioid subtype or endometrioid grade 3. 
¶ Cox Proportional Hazard Model. The adjusted HR is based on multivariate analyses including all 
the variables listed on the same line. 




Table 5 (Suppl) 
Interobserver variability for tumor diameter measurements by 3 observers 
 
 Mean  Mean difference (SD)  ICC MDC 







 Obs 1/2 Obs 1/3 Obs 2/3    
           
           
Transverse 
diameter 
32 26 27  6 (10) 4 (11) 2 (8)  0.78  
(0.73-0.82) 
21 
           
           
Anterioposterior 
diameter 
20 17 18  2 (7) 2 (8) 0 (6)  0.85  
(0.81-0.88) 
14 
                
           
Sagittal 
diameter 
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Background: Improved methods for preoperative risk stratification in endometrial cancer are highly requested by gyne-
cologists. Texture analysis is a method for quantification of heterogeneity in images, increasingly reported as a promis-
ing diagnostic tool in various cancer types, but largely unexplored in endometrial cancer.
Purpose: To explore whether tumor texture parameters from preoperative MRI are related to known prognostic fea-
tures (deep myometrial invasion, cervical stroma invasion, lymph node metastases, and high-risk histological subtype)
and to outcome in endometrial cancer patients.
Study type: Prospective cohort study.
Population/Subjects: In all, 180 patients with endometrial carcinoma were included from April 2009 to November 2013
and studied until January 2017.
Field Strength/Sequences: Preoperative pelvic MRI including contrast-enhanced T1-weighted (T1c), T2-weighted, and
diffusion-weighted imaging at 1.5T.
Assessment: Tumor regions of interest (ROIs) were manually drawn on the slice displaying the largest cross-sectional
tumor area, using the proprietary research software TexRAD for analysis. With a filtration-histogram technique, the tex-
ture parameters standard deviation, entropy, mean of positive pixels (MPP), skewness, and kurtosis were calculated.
Statistical Tests: Associations between texture parameters and histological features were assessed by uni- and multivar-
iable logistic regression, including models adjusting for preoperative biopsy status and conventional MRI findings. Multi-
variable Cox regression analysis was used for survival analysis.
Results: High tumor entropy in apparent diffusion coefficient (ADC) maps independently predicted deep myometrial
invasion (odds ratio [OR] 3.2, P< 0.001), and high MPP in T1c images independently predicted high-risk histological
subtype (OR 1.01, P5 0.004). High kurtosis in T1c images predicted reduced recurrence- and progression-free survival
(hazard ratio [HR] 1.5, P< 0.001) after adjusting for MRI-measured tumor volume and histological risk at biopsy.
Data Conclusion: MRI-derived tumor texture parameters independently predicteddeepmyometrial invasion, high-risk histolog-
ical subtype, and reduced survival in endometrial carcinomas, and thus, represent promising imaging biomarkers providing a
more refined preoperative risk assessment thatmay ultimately enable better tailored treatment strategies in endometrial cancer.
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Tumor heterogeneity is a key feature of malignant disease.Several pan-cancer analyses, comprising a variety of can-
cer types, have reported intratumor genetic heterogeneity to
be associated with tumor aggressiveness and reduced sur-
vival.1,2 Mechanisms proposed to explain the aggressive
behavior of heterogeneous tumors include Darwinian selec-
tion among clones enabling tumor adaptation and drug
resistance.3
Texture analysis (TA), a method for quantification of
heterogeneity in images, has become an important element
in the growing field of radiomics, the science of high-
throughput extraction of quantitative features from radiolog-
ical imaging data.4 Although radiomics inherently operates
at a more macroscopic level than genomics and histological
markers, the method has proven useful in medical diagnostic
imaging, especially in oncological imaging.5 Magnetic reso-
nance imaging (MRI)- and computed tomography (CT)-
derived texture parameters have been proposed as tools for
accurate diagnosis, preoperative risk stratification, or assess-
ment of treatment response in several cancer types, eg, in
the brain,6 lung,7 breast,8 and prostate.9 A recent prelimi-
nary study also reported MR texture analysis (MRTA) as a
useful tool for preoperative risk stratification in endometrial
cancer.10
Endometrial cancer is the most common gynecologic
malignancy in industrialized countries, with an increasing
incidence.11 Treatment strategy and prognosis are tradition-
ally based on the International Federation of Gynecology
and Obstetrics (FIGO) stage and histological subtype and
grade determined from the hysterectomy specimen.12,13 To
enable more individualized surgical treatment, improved
methods for preoperative risk stratification methods are
highly warranted.
MRI is widely used for preoperative assessment of
endometrial cancer.14–16 However, conventional MRI has
confirmed shortcomings in predicting FIGO stage,16,17 and
interobserver variability between radiologists also represents
a source of inaccuracy.18 Advances in MRI technology have
increasingly enabled quantitative and functional imaging.
Diffusion-weighted imaging (DWI), reflecting tumor micro-
structure, dynamic contrast-enhanced (DCE)-MRI, and MR
spectroscopy (MRS), reflecting tumor physiology and
metabolism, may to an extent reduce the subjectivity in the
assessment of endometrial cancers and yield novel bio-
markers for preoperative risk stratification. Still, overtreat-
ment at primary surgery (eg, unnecessary lymphadenectomy
in low-risk patients) may represent a problem. In this
regard, MRTA could potentially enhance the role of diag-
nostic imaging and refine the preoperative risk assessments.
This large, population-based study aimed to explore
whether the staging parameters deep (50%) myometrial
invasion (DMI), cervical stroma invasion (CSI), and lymph
node metastases (LNM), high-risk histological subtype, and




This prospective study was conducted under Institutional Review
Board approval with written informed consent from all patients.
From April 2009 to November 2013, preoperative pelvic MRI was
performed in a population-based cohort of 252 patients with sus-
pected endometrial cancer. The final histological diagnosis based
on hysterectomy specimen did not confirm endometrial cancer in
36 patients and these were excluded. Thus, 216 consecutive
patients with endometrial cancer, histologically verified at subse-
quent staging, were included in the study cohort. All patients were
diagnosed and treated at the same university hospital, which is a
European Society of Gynaecological Oncology accredited center.
The last follow-up was in January 2017 and mean follow-up time
for the group of patients without recurrence or progression was 51
months (range 0–85).
Imaging Protocol
MRI was performed on a 1.5T Siemens Avanto running Syngo
MR B17 (Erlangen, Germany) using a six-channel body coil. Prior
to imaging, 20mg butylscopolamine bromide (Buscopan, Boeh-
ringer, Ingelheim, Germany) was administered intravenously.
Based on the Guidelines of the European Society of Urogen-
ital Imaging (ESUR),15 the MRI protocol included pelvic sagittal
and axial oblique (perpendicular to the long axis of uterus) T2-
weighted images and axial oblique T1-weighted images obtained
before and after intravenous contrast administration (Dotarem,
Guerbet, Villepinte, France: 0.1 mmol gadolinium per kg of body
weight, 3ml/s injection speed) using a 2-minute delay.18 T2 images
were acquired using 2D spin echo sequences (repetition time (TR)
/ echo time (TE)5 6310/95 msec [for sagittal images TR/
TE5 4920/95], matrix5 256 3 256, field of view [FOV]5 180
3 180mm2, section thickness5 3mm, averages5 2 [for sagittal
images averages5 3]) yielding a voxel size of 0.7 3 0.7 3
3.0mm. T1 images were acquired using a 3D volumetric interpo-
lated breath-hold (VIBE) gradient echo sequence with fat satura-
tion (TR/TE5 7.23/2.55 msec, matrix5 192 3 192, FOV5 250
3 250mm2, section thickness5 2mm, averages5 1) yielding a
voxel size of 1.3 3 1.3 3 2.0mm.
Pelvic DWI was acquired using an axial oblique 2D spin-
echo echo planar imaging sequence with b-values of 0 and 1000 s/
mm2 (TR/TE5 3100/79 msec, matrix5 128 3 128, FOV5 300
3 300mm2, section thickness5 5mm, averages5 12). Apparent
diffusion coefficient (ADC) maps were generated with voxel size
2.3 3 2.3 3 5mm.
Histological Diagnosis
Mean (range) interval between MR examination and surgical stag-
ing was 11 (0–98) days.
The preoperative biopsy was graded as either low-risk (endo-
metrioid grade 1–2) or high-risk (endometrioid grade 3 or nonen-
dometrioid) endometrial cancer. From preoperative endocervical
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curettage, an assessment of cervical tumor involvement was also
performed.
All patients were surgicopathologically staged according to
the 2009 FIGO staging system.12 Hysterectomy specimens were
sectioned along the longitudinal plane of the uterus, and myome-
trial invasion and cervical stromal invasion were estimated grossly
and confirmed microscopically according to standard criteria.19
Image Analysis
One radiologist (SYH, with 5 years of experience in pelvic MRI),
blinded for clinical and histological data, assessed the eligibility of
the images for MRTA. Of the 216 scanned patients, 33 were
excluded due to small or poorly defined tumors, and three due to
major image artifacts. Thus, 180 patients were included for
MRTA; three of these had major artifacts on DWI only. Contrast-
enhanced T1-weighted images (T1c, n5 180), T2-weighted images
(T2, n5 180), and ADC-maps (n5 177) were exported to the
commercially available research software TexRAD (TexRAD, part
of Feedback, Cambridge, UK). Median (range) region of interest
(ROI) sizes were in T1c images 169 (24–1760) voxels, in T2
images 593 (45–4970) voxels, and in ADC maps 73 (10–654)
voxels.
Results from conventional MRI (assessment of tumor size,
myometrial and cervical invasion and presence of lymph node
metastases) were recorded as consensus opinion from three radiol-
ogists (median values for continuous variables and majority for cat-
egorical variables) having independently read the same MR images
in a prior study.20
Texture Analysis
In TexRAD, one radiologist (SYH) manually drew ROIs separately
on T1c images, T2 images, and ADC-maps, aiming at including all
viable tumor tissue on the slice displaying the largest cross-
sectional tumor area (Fig. 1). The ROIs were processed using a
filtration-histogram technique based on Laplacian of Gaussian spa-
tial bandpass filtering, in which image elements of different sizes
were enhanced corresponding to spatial scale filter (SSF) from 2–
6mm, ie, fine (2mm), medium (3–5mm), and coarse texture
(6mm) (Fig. 1). Based on texture quantification in tumor ROIs,
the parameters mean intensity, standard deviation (SD), entropy,
mean of positive pixels (MPP), skewness, and kurtosis were calcu-
lated. The mean intensity does not reflect heterogeneity per se, and
thus, this feature was omitted in further analyses. MPP in unfil-
tered MR images (SSF5 0) equals mean intensity and was also
omitted. Thus, the total number of texture parameters included in
the statistical analyses was 87 (combinations of T1c/T2/ADC-map,
SD/entropy/skewness/MPP/kurtosis at SSF 0/2/3/4/5/6). A con-
densed notation is used in this article, eg, ADC_Entropy6, indicat-
ing tumor ROI entropy in ADC-map at SSF 6.
Statistical Analysis
The majority of texture parameters did not have normal distribu-
tion, thus nonparametric tests were used. Mann–Whitney U-test
assessed the ability of texture parameters to predict DMI, CSI,
LNM, and high-risk histological subtype (endometrioid grade 3 or
nonendometrioid). The texture parameters were subsequently
ranked according to lowest P-value, and the best predictors selected
for receiver operator characteristic (ROC) curve analyses and uni-
variable and multivariable logistic regression. In the multivariable
analyses, we adjusted for MRI-measured tumor volume, conven-
tional MRI reading results, and preoperative biopsy risk status.
When comparing the diagnostic performance of texture variables
with conventional MRI reading results, McNemar’s test was used.
In this analysis, cutoffs for texture variables were determined by
ROC curve analysis selecting the highest Youden index. Spearman’s
bivariate correlation test was used to explore correlations.
Survival analysis was performed for each of the texture
parameters separately in univariable Cox regression analysis for pre-
dicting recurrence- and progression-free survival (RPFS), ie, time
to recurrence (for patients considered to be cured by primary treat-
ment) or progression (for patients known to have residual disease
after primary treatment). Ranked according to lowest P-value, the
best predictor was selected to be included in a multivariable analy-
sis also including MRI-measured tumor volume and preoperative
FIGURE 1: Endometrial carcinoma manually segmented (blue line) on contrast-enhanced T1-weighted (T1c) image (upper row), T2-
weighted (T2) image (middle row), and ADC-map (lower row) from the same 52-year-old postmenopausal woman diagnosed with
stage 1b endometrial cancer (endometrioid, grade 1). Successive filtered images (spatial scale of filtration [SSF] 2–6) to the right
of each native image.
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biopsy risk status. For the top-ranked texture parameters, differ-
ences in RPFS were assessed by the Mantel–Cox test and Kaplan–
Meier plots.
Based on the findings of extensive correlations among the 87
texture parameters (Suppl. Tables 1–3), a customized modification
of Bonferroni correction was applied, in which the number of
effective tests was arbitrarily estimated at 25, yielding a significance
level of 0.002. In the multivariable analyses a traditional signifi-
cance level of 0.05 was used. The data were analyzed using SPSS
23.0 (IBM, Armonk, NY).
Results
Patients
Mean patient age at primary treatment in the study sample
(n5 180) was 67 years (Table 1). Primary surgical treatment
included bilateral salpingo-oophorectomy and hysterectomy
for 98% (177/180), tumor reduction surgery for 1/180, and
curettage only for 2/180. Lymphadenectomy was performed
in 86% (154/180), pelvic only in 126 patients, and pelvic
and para-aortic in 28 patients. In patients who underwent
lymphadenectomy, the mean number of resected nodes was
18 (range 1–54). Adjuvant therapy was given to 39% (70/
180); comprising chemotherapy in 83% (58/70), radiother-
apy (external or internal) in 16% (11/70), and hormonal
treatment in 1% (1/70). Further details on patient and
tumor characteristics are given in Table 1.
Overall Evaluation of Texture Parameters
A summary of the texture features SD, entropy, MPP, skew-
ness, and kurtosis significantly predicting high-risk endome-
trial cancer is given in Fig. 2, depicting the number of
texture variables (combinations of T1c/T2/ADC-map at SSF
TABLE 1. Patient and Tumor Characteristics for 180
Endometrial Carcinoma Patients Studied
Age, mean (range) 67 (41–93)
BMI, mean (range) 28 (16–50)
Postmenopausal, n (%) 166 (93%)









Histologic subtype, n (%)
Endometrioid 142 (79%)




Histological grade in endometrioid tumors, n (%)
Grade 1 64 (45%)
Grade 2 46 (32%)
Grade 3 30 (21%)
FIGO stage refers to the International Federation of Gynecol-
ogy and Obstetrics stage according to 2009 criteria. BMI, body
mass index.
FIGURE 2: Proportions of the respective texture parameters
predicting presence of deep myometrial invasion, cervical
stroma invasion, lymph node metastases, and high-risk histo-
logical subtype at significance level of 0.05 (a) and at signifi-
cance level of 0.002 (b) are given in the bars. Up arrows
indicate that high values for the respective texture parameter
predict high-risk cancer (positive staging parameters/high-risk
histology), whereas down arrows indicate that low values for
the respective texture parameters predict high-risk cancer.
Notice the consistency and high proportion of entropy- and
kurtosis-based parameters being significant predictors of high-
risk cancer. The feature MPP also yielded a high proportion of
significant predictors. Low values of MPP in T2 images predict-
ing high-risk cancer, as opposed to high values in T1c images
and ADC-maps, is explainable by the reciprocal nature of dif-
ferent MRI sequences. ADC, apparent diffusion coefficient
(maps); MPP, mean of positive pixels; MRI, magnetic resonance
imaging; SD, standard deviation; T1c, contrast-enhanced T1-
weighted (images); T2, T2-weighted (images).
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0/2/3/4/5/6) predicting DMI, CSI, LNM, and high-risk his-
tological subtype. Entropy, followed by MPP and kurtosis,
had the highest proportion of significant predictors, whereas
skewness and SD yielded fewer significant predictors. For
the feature SD there was also inconsistency in terms of both
high values (T1c images and ADC-maps) and low values
(T2 images) predicting high-risk cancer. High values of
entropy and kurtosis (in T1c images, T2 images, and ADC
maps) consistently predicted high-risk cancer, whereas low
values of MPP and skewness in T2 images predicted high-
risk cancer, as opposed to high values in T1c images and
ADC maps (Fig. 2, arrows). The top-ranked texture param-
eters for prediction of deep myometrial invasion, cervical
stroma invasion, lymph node metastases, high-risk histologi-
cal subtype, and recurrence- and progression-free survival,
respectively, are given in Table 2.
The texture parameters based on the same MRI
sequence and texture feature, ie, only differing in filter level,
were highly correlated (Suppl. Tables 1–3). For entropy, this
was particularly striking, with correlation coefficients rang-
ing from 0.86 to 1.00.
Prediction of Deep Myometrial Invasion (DMI)
Of the 87 texture parameters assessed, 44 significantly
(P< 0.002) predicted DMI in univariable analysis. The
majority of these comprised the parameters entropy, MPP
and kurtosis, among which the top 10 all comprised
entropy (Suppl. Table 4). The top-ranked predictor of
DMI, entropy in ADC-maps at filter level 6 (ADC_En-
tropy6), using a cutoff value of 4.49, yielded significantly
higher accuracy and specificity than conventional MRI read-
ing (0.78 vs. 0.70, P5 0.015 and 0.84 vs. 0.69, P5 0.004,
respectively) (Table 3). In a multivariable analysis,
ADC_Entropy6 independently predicted DMI with an odds
ratio of 3.2 (95% confidence interval 1.7–6.1, P< 0.001)
when adjusting for high-risk status based on preoperative
biopsy (endometrioid grade 3 or nonendometrioid), conven-
tional MRI reading suggesting DMI, and MRI-measured
tumor volume (Table 4). The ROC curve yielded an area
under the ADC_Entropy6 ROC-curve (AU-ROC) of 0.81
(P< 0.001) (Fig. 3a) for prediction of DMI.
Prediction of Cervical Stroma Invasion (CSI)
For prediction of CSI in univariable analysis, none of the
87 texture parameters reached the significance level of
0.002. The top-ranked predictor of CSI, MPP in T2 images
at filter level 4 (T2_MPP4), using a cutoff value of 137,
yielded lower accuracy and specificity than conventional
MRI reading (0.74 vs. 0.82, P< 0.001 and 0.78 vs. 0.93,
P< 0.001, respectively) (Table 3). Furthermore, T2_MPP4
did not independently predict CSI when adjusting for pre-
operative endocervical curettage indicating cervical tumor
invasion, conventional MRI reading suggesting CSI, and
MRI-measured tumor volume (Table 4). The corresponding
AU-ROC for T2_MPP4 was 0.64 (P5 0.01) (Fig. 3b) for
prediction of CSI.
Prediction of Lymph Node Metastases (LNM)
Five out of 87 texture parameters were significant (P<
0.002) predictors of LNM in univariable analysis, all five
parameters being entropy in T1c images at different filter
levels (Suppl. Table 4). However, the top-ranked parameter,
entropy in T1c images at filter level 6 (T1c_Entropy6),
using a cutoff value of 5.31, had lower accuracy and specif-
icity than conventional MRI reading (0.72 vs. 0.90, P<
0.001 and 0.73 vs. 0.97, P< 0.001) (Table 3). In the multi-
variable analysis, T1c_Entropy6 did not independently pre-
dict LNM, when adjusting for high-risk status in
preoperative biopsy, conventional MRI reading suggesting
LNM and MRI-measured tumor volume (Table 4). The
corresponding AU-ROC for T1c_Entropy6 was 0.73
(P5 0.001) (Fig. 3c) for prediction of LNM.
Prediction of High-Risk Histological Subtype
Sixteen of the tested 87 texture parameters were significant
(P< 0.002) predictors of high-risk histological subtype
(endometrioid grade 3 and nonendometrioid tumors) in
univariable analysis. The majority of these parameters com-
prised entropy, and the remaining MPP (Suppl. Table 4).
The top-ranked predictor, MPP in T1c images at filter level
4 (T1c_MPP4), independently predicted high-risk histologi-
cal subtype with an odds ratio of 1.01 (1.00–1.01,
P5 0.004) when adjusted for high-risk status based on pre-
operative biopsy and MRI-measured tumor volume (Table
4). The corresponding AU-ROC for T1c_MPP4 was 0.66
(P< 0.001) (Fig. 3d) for prediction of high-risk histological
subtype.
Survival Analysis
Thirteen out of 87 texture parameters significantly (P<
0.002) predicted RPFS in univariable Cox regression analy-
sis (Suppl. Table 4). The top-ranked prognostic texture
parameter, kurtosis in T1c images at filter level 2 (T1c_Kur-
tosis2), independently predicted reduced survival with a haz-
ard ratio of 1.5 (1.2–2.0, P< 0.001) when adjusted for
high-risk status based on preoperative biopsy and MRI-
measured tumor volume (Table 5). Significantly different
RPFS was observed in patients based on the two highest-
ranked tumor texture parameters in the Cox analysis:
T1c_Kurtosis2 and ADC_Entropy6 (also the best predictor
of DMI) when grouping patients according to the textural
tumor parameter being below or at/above median value
(Fig. 4a,b). The proportion of patients given adjuvant treat-
ment was higher in the poor outcome groups: 51% received
adjuvant treatment among patients with T1c_Kurtosis2 at or
above the median value (poor outcome group, Fig. 4a).
Only 27% received adjuvant treatment among patients with
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T1cKurtosis2 below the median value. Similarly, for patients
with ADC_Entropy6 at or above the median value, 51%
received adjuvant treatment compared to 26% among
patients with ADC_Entropy6 below the median value.
Discussion
In this large, population-based study we demonstrated that
texture parameters derived from preoperative MRI are sig-
nificantly associated with high-risk disease and reduced
survival in endometrial cancer. Our findings suggest that
tumor texture analysis yields clinically relevant imaging
markers that may aid in the preoperative staging and risk
assessment.
Surgical staging and subsequent histological assessment
have traditionally been the primary basis for treatment and
prognostication in endometrial cancer, thereby allowing only
limited risk stratification prior to surgery. In this study, we
link novel MRI features to established risk factors in endo-
metrial cancer, and identify tumor texture parameters that
noninvasively and accurately predict high-risk status preop-
eratively. Compared to conventional anatomical MRI inter-
pretation, the top-ranked texture parameter ADC_Entropy6
has significantly higher accuracy for prediction of DMI.
Also in multivariable analyses, when adjusting for other rele-
vant markers available preoperatively, the texture parameters
remain significant and independent predictors of DMI
(ADC_Entropy6) and high-risk histological subtype
(T1c_MPP4). Similarly, in the survival analysis the top-
ranked texture parameter, T1c_Kurtosis2, is a significant
and independent predictor of RPFS, comparable to MRI-
measured tumor volume, which has previously been
reported as a strong prognostic factor.21 Differences in adju-
vant treatment in the study population could theoretically
influence survival, since adjuvant treatment expectedly
improves survival. However, since adjuvant treatment was
more frequently administered in the poor outcome group
when stratifying patients according to the highest-ranked
texture features (Fig. 4), this seems highly unlikely to have
biased our results.
Interestingly, a recent preliminary MRI study using
TexRAD in endometrial cancer10 found that a subset of 11
texture parameters jointly predicted DMI with an AU-ROC
of 0.84. Similarly, in our study the top-ranked single param-
eter, ADC_Entropy6, predicted DMI with an AU-ROC of
0.81. For prediction of high-grade tumor, a subset of 16
texture parameters jointly yielded an AU-ROC of 0.83,10
whereas the top-ranked single parameter in our study,
T1c_MPP4, yielded an AU-ROC of 0.66. However, in spite
of being based on somewhat different approaches, both
studies suggest a very promising role of MRI texture analysis
for better preoperative risk assessment in endometrial
cancer.
In our study, comprising tumor texture analysis of T1c
images, T2 images, and ADC-maps, we found the parameters
entropy, MPP, and kurtosis to be associated with high-risk
endometrial cancer to a larger extent than SD and skewness.
As the texture features are pure mathematical descriptors of
histogram shape, their biological correlates are somewhat
unclear, and very few publications have tried to translate these
features into structural or physiological tissue characteristics.22
TABLE 3. Diagnostic Performance of Top-Ranked Tumor Texture Parameters Using Cutoffs and of Conventional
MRI Readings for Assessment of Key Staging Parameters in Endometrial Cancer
Sensitivity Specificity Accuracy
Deep myometrial invasion ADC_Entropy6a> 4.49 0.70 (53/76) 0.84 (83/99) 0.78 (136/175)
MRI reading DMI1 0.72 (55/76) 0.69 (68/99) 0.70 (123/175)
[P5 0.82] [P5 0.004] [P5 0.015]
Cervical stroma invasion T2_MPP4b< 137 0.53 (17/32) 0.78 (114/146) 0.74 (131/178)
MRI reading CSI1 0.31 (10/32) 0.93 (136/146) 0.82 (146/178)
[P5 0.12] [P< 0.001] [P< 0.001]
Lymph node metastases T1c_Entropy6c> 5.31 0.68 (13/19) 0.73 (99/135) 0.72 (112/154)
MRI reading LNM1 0.42 (8/19) 0.97 (131/135) 0.90 (139/154)
[P5 0.13] [P< 0.001] [P< 0.001]
aHighest ranked texture parameter for prediction of myometrial invasion.
bHighest ranked texture parameter for prediction of cervical stroma invasion.
cHighest ranked texture parameter for prediction of lymph node metastases. Cutoffs for texture variables are determined by ROC-
curve analysis selecting the highest Youden index. Significant differences in diagnostic performance (P< 0.05) are given in bold. P-val-
ues refer to McNemar’s test. ADC, apparent diffusion coefficient (maps); CSI, cervical stroma invasion; DMI, deep myometrial inva-
sion; LNM, lymph node metastases; MPP, mean of positive pixels; MRI, magnetic resonance imaging; ROC, receiver operator
characteristics; T1c, contrast-enhanced T1-weighted (images); T2, T2-weighted (images).
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However, entropy reflects textural irregularity and is clearly
linked to tissue heterogeneity. MPP is a TexRad specific fea-
ture, which in MRI is relevant only in filtered images, ie,
when pixels are recoded into a range of positive values or
negative values according to their native values. Consequently,
MPP reduces the impact of dark objects in the image (eg,
nonenhancing fluid collections in T1c images), as elaborated
in a review by Miles et al.23 Kurtosis reflects the shape of the
histogram in terms of pointedness, taking into account the
relation between centrum and periphery, ie, high kurtosis typ-
ically reflects frequent extreme deviations, as opposed to fre-
quent modestly sized deviations yielding lower kurtosis
values. When applied to T1c images, T2 images, and ADC
maps, the texture parameters in particular reflect heterogene-
ity in terms of neoangiogenesis, cellular distribution, and cel-
lular density, respectively.22 The TexRad-specific filtering
algorithm is hypothesized to enhance the biologically relevant
information in medical images.23 Among our high-ranked
predictors, we found texture parameters of all filter levels,
often highly correlated. We did not see a clear pattern in
which certain filter levels had a better predictive or prognostic
performance than others. This observation complies with pre-
vious TexRad-based publications, including the previous
endometrial cancer study, in which no specific filter level has
proven general superiority.10 Our findings also illustrate some
of the diversity and complexity of radiomics; characterizing
cancers of different origin, type, subtype, and grade, using
images originating from different modalities and protocols
and employing image analyses being inherently software- and
operator-dependent.
In routine clinical practice, conventional MRI is
widely established as a useful tool in the preoperative
assessment of endometrial cancer. Adding texture analysis
does not increase scan time, nor patient-related side effects.
TABLE 4. Univariable and Multivariable Logistic Regression for Prediction of Deep Myometrial Invasion, Cervical













Deep myometrial invasion ADC_Entropy6 4.7 (2.8–7.8) <0.001 3.2 (1.7–6.1) <0.001
MRI tumor volume 1.05 (1.03–1.07) <0.001 1.01 (0.99–1.03) 0.36
MRI reading DMI1 5.3 (2.8–10.1) <0.001 2.0 (0.9–4.4) 0.08
High-risk biopsya 1.2 (0.6–2.2) 0.66 0.7 (0.3–1.6) 0.41
Cervical stroma invasion T2_MPP4 0.995 (0.99–1.00) 0.03 0.996 (0.99–1.00) 0.11
MRI tumor volume 1.006 (1.00–1.01) 0.02 0.999 (0.99–1.01) 0.77
MRI reading CSI1 6.2 (2.3–16.6) <0.001 4.5 (1.4–14.3) 0.01
Biopsy Cervix1 2.2 (1.2–3.9) 0.01 2.0 (1.1–3.9) 0.03
Lymph node metastases T1c_Entropy6 3.1 (1.5–6.6) 0.003 1.7 (0.7–4.3) 0.26
MRI tumor volume 1.02 (1.01–1.03) 0.007 1.01 (0.99–1.03) 0.43
MRI reading LNM1 23.8 (6.2–91.8) <0.001 14.0 (3.2–61.0) <0.001
High-risk biopsya 3.0 (1.1–8.0) 0.03 1.6 (0.5–5.2) 0.45
High-risk histological subtypea T1c_MPP4 1.01 (1.00–1.01) 0.001 1.01 (1.00–1.01) 0.004
MRI tumor volume 1.02 (1.01–1.04) <0.001 1.02 (1.00–1.04) 0.02
High-risk biopsya 22.7 (9.5–54.4) <0.001 24.6 (9.6–63.5) <0.001
The top-ranked texture parameter is included in each category.
aHigh-risk histological subtype is defined as endometrioid grade 3 or nonendometrioid subtype as opposed to low-risk histological
subtype defined as endometrioid grade 1 and 2. Similarly, high-risk biopsy is defined as endometrioid grade 3 or nonendometrioid
subtype.
Cervical tumor involvement in the preoperative endocervical curettage is notated Biopsy Cervix1.
Significant P values (after modified Bonferroni correction in univariable analysis (P< 0.002) and P< 0.05 in multivariable analysis)
are given in bold.
ADC, apparent diffusion coefficient (maps); CI, confidence interval; CSI, cervical stroma invasion; LNM, lymph node metastases;
MPP, mean of positive pixels; MRI, magnetic resonance imaging; OR, odds ratio; T1c, contrast-enhanced T1-weighted (images); T2,
T2-weighted (images).
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With a PACS-integrated software, texture analysis can be
executed with only a few minutes operator time per case.
The decisive steps are image selection and tumor segmenta-
tion, which in our study were done manually. With advan-
ces in technology, semiautomated and automated tumor
segmentation is increasingly available. However, this
approach was not within the scope of our study. Extending
the analysis from a 2D approach (largest cross-sectional
tumor area) to a 3D approach (whole tumor) would also
be more feasible based on automatic segmentation. One
publication on CT texture analysis of colorectal cancer com-
pared the 2D to 3D approach and found 3D analysis to be
slightly more representative of tumor heterogeneity and
yielded better prognostic information.24 This was, however,
a relatively small (n5 55) and retrospective study, and the
benefit of the 3D approach should be further evaluated—
also taking into account its time-consuming nature.
Our study has some limitations. First, the study was
conducted in a single institution using a standardized imag-
ing protocol. Thus, our results are not necessarily generally
applicable to different scanners or patient populations.
However, the imaging protocol was largely based on ESUR
guidelines and would be expected to be similar in clinical
practice elsewhere. Second, intra- and interobserver
FIGURE 3: Receiver operator characteristics (ROC) curves visualizing the diagnostic performance of the top-ranked texture param-
eters for predicting presence of the staging parameters deep myometrial invasion (a), cervical stroma invasion (b), lymph node
metastases (c), and for high-risk histological subtype (d). ADC_entropy6 yielded an area under the curve (AUC) of 0.81 (P< 0.001)
for prediction of deep myometrial invasion (a), T2_MPP4 an AUC of 0.64 (P50.01) for prediction of cervical stroma invasion (b),
T1c_Entropy6 and AUC of 0.73 (P50.001) for prediction of lymph node metastases (c), and T1c_MPP4 and AUC of 0.66 (P<
0.001) for prediction of high-risk histological subtype (d). P-values refer to the test of equal areas under the diagonal and the
ROC-curve.
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variability for the texture measurements was not assessed in
this study, which was based on manual segmentation. Valid,
automated tumor segmentation tools could potentially over-
come interobserver variability, and this should be explored
in future research. Lastly, the histogram-based approach in
TexRAD does not cover all aspects of texture analysis. Our
findings should encourage future research with even more
sophisticated image texture analysis.
In summary, preoperative tumor texture analysis from
MRI independently predicts high-risk disease and reduced
survival in endometrial cancer. This approach using texture
analysis to yield prognostic biomarkers may ultimately guide
tailored treatment in endometrial cancer. However, the value
of image texture analysis in endometrial cancer needs to be
further evaluated and validated across observers, centers, and
platforms prior to potential implementation in the clinic.
FIGURE 4: Kaplan–Meier curves depicting significantly different patient survival for the two highest-ranked tumor texture parame-
ters: T1c_Kurtosis2 (a) and ADC_Entropy6 (b). High tumor values for T1c_Kurtosis2 (a) and for ADC_Entropy6 (b) were significantly
associated with reduced recurrence- and progression free survival (P50.0004 and P50.004, respectively). P-values refer to the
Mantel–Cox (log-rank) test.












T1c_Kurtosis2 1.7 (1.3–2.3) <0.001 1.6 (1.2–2.1) 0.003
T1c_Entropy6 2.1 (1.4–3.2) <0.001 0.7 (0.2–2.5) 0.61




T1c_Kurtosis2 1.7 (1.3–2.3) <0.001 1.5 (1.2–2.0) <0.001
MRI tumor volume 1.01 (1.00–1.01) <0.001 1.01 (1.00–1.01) 0.007
High-risk biopsya 4.3 (2.3–8.0) <0.001 3.4 (1.8–6.4) <0.001
aCategorical variable. High-risk biopsy is defined as endometrioid grade 3 or nonendometrioid subtype as opposed to low-risk com-
prising endometrioid grades 1 and 2.
Significant P values (after modified Bonferroni correction in univariable analysis (P< 0.002) and P< 0.05 in multivariable analysis)
are given in bold.
ADC, apparent diffusion coefficient (maps); CI, confidence interval; HR, hazard ratio; MRI, magnetic resonance imaging; T1c,
contrast-enhanced T1-weighted (images).
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